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Abstract 
A novel quinolone resistance mechanism was discovered in the last decade. 
Plasmid-mediated quinolone resistance (qnr) genes, which encode the Qnr proteins, 
protect the quinolone targets from inhibition, leading to resistance. These qnr-
harboring organisms have been identified in many parts of the world, but data is 
sparse in Asian countries, including Hong Kong. In addition, little is known about its 
clinical relevance, particularly in the seriously i l l hospitalized patients. In this study, 
the prevalence of qnr genes in selected Enterobacteriaceae isolates from a cohort of 
bacteraemic hospitalized patients, the antimicrobial susceptibility profile of these 
isolates, their association with other bacterial resistance genotypes, and the clinical 
characteristics and outcomes of patients were investigated. 
A prospective study was conducted during the period of Jan 2008 to Apr 
2009. A total of 950 non-duplicate, consecutive blood Enterobacteriaceae isolates 
were collected real-time. A total of 204 Extended-spectrum p-lactamase (ESBL)-
and/or plasmid-mediated AmpC (PMAmpC)-producers were detected, and 
underwent further study: antimicrobial susceptibilities were determined, and qnr 
genes and bla genes were detected using PCR. Al l gwr-positive isolates and the co-
existed bla genes were sequenced and characterized. The clinical data of these 204 
patients were recorded and analyzed. 
High prevalence (n = 42, 20.6%) of ^wr genes was detected in ESBL- and/or 
PMAmpC-producing blood isolates (Escherichia coli, 71.6%, Klebsiella spp. 17.6%, 
ii 
Enterobacter spp. 7.4% Citrobacter spp. 2.0% and Serratia spp. 1.5%). Twenty-six 
(12.7%) and 16 (7.8%) isolates carried qnrB and qnrS genes respectively. None of 
them carried qnrA genes and no single isolate carried more than one type of qnr 
genes. Most of these gnr-positive isolates (80.9%) were Klebsiella spp. They 
frequently co-existed with bla genes including DHA-1，SHV-11，CTX-M-14 and 
TEM-1. The ^wr-positive isolates conferred 'low-level' fluoroquinolone resistance 
and they showed higher rates of p-lactam/p-lactamase inhibitor resistance, and more 
frequently co-existence with the PMAmpC genes when compared to ^wr-negative 
isolates. History of solid tumour and hospital-acquired infection were more 
commonly identified in the gwr-positive group. The overall 30-day mortality rate in 
the study cohort was 27.5% (56/204). The 30-day mortality rate (47.6%) was 
significantly higher in the ^wr-positive group (P<0.05). Multivariate Cox regression 
analysis suggested that development of pneumonia, failure to receive susceptible 
antibiotics, and higher Pitt bacteraemia score were the possible explanations for their 
high mortality. 
In conclusion, high prevalence of qnr genes was found in our 
Enterobacteriaceae blood isolates, which were multi-drug resistant. The emergence 
of high-level fluoroquinolone resistance may further limit the therapeutic choice. 
Furthermore, these strains are likely capable to transfer qnr genes together with bla 
genes horizontally, and disseminate rapidly through plasmids. Therefore, continuous 
monitoring of these resistant strains and their antimicrobial susceptibility profiles, 
particularly among the ESBL-^MAmpC-producers is needed; and infection control 
measures should be strictly adhered to prevent dissemination of these resistant 
organisms. 
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論文摘要 
過去十年，_種嶄新的喹諾酮抗藥性機制被發現。該抗藥性機制是由質粒介 
導的喹諾酮抗藥性基因（^厂基因）編碼的蛋白（0爪蛋白），保護喹諾酮的目標而免受 
藥物抑制的。這些載有(7^基因的菌株（…〃菌株）在世界許多地方被發現，但在亞洲 
地區（包括香港）所知的甚少。再者，有關（7^*基因與醫學臨床相關性，尤其在住院 
的重症病患中所知的更少。為此，本研究篩選一批來自住院的敗血症病患的腸捍菌科 
菌株，探究其卯^基因的普遍性及藥敏型式，並對^^菌株與其他抗藥性基因型、病 
患臨床特徵及結果的關係作出分析。 
此前瞻性研究於二零零八年一月至二零零九年四月期間進行。研究即時收集共 
950株非重複性、連續並在血液培養中所獲的腸桿菌科菌株。其中204株被檢測為 
超廣譜乙內醯胺酶及/或質粒介導的AmpC乙內醯胺酶的生產者則用於進一步研究： 
包括測定其藥敏型式及利用聚合酶鏈反應作例^基因及乙內醯胺酶基因（办总基因）檢 
定。所有^厂基因檢定呈陽性反應並同時載有/？冶基因的菌株均作脱氧核糖核酸序列 
分析及分類。此外，本研究亦收集並記錄提供以上204株菌株的病患臨床資料作出 
分析。 
在血液培養中所獲得的、生產超廣譜乙內醯胺酶及/或質粒介導的AmpC乙內 
醯胺酶的菌株（大腸捍菌佔71.6%、克雷白氏菌屬佔17.6%、腸桿菌屬佔7.4%、檸 
檬酸捍菌屬佔2.0%及沙雷氏菌屬佔1.5%)中^77厂基因呈高普遍性（n=42，20.6%)。 
研究發現其中26株（12.7°/。)及16株（7.8%)分別載有qnB及qnrS基因，但未有發 
現載有^7^基因或同時載有一種以上7^*基因的菌株。菌株大部分（80.9%)為克雷 
白氏菌屬。它們往往同時並存著包括DHA-1、SHV-11、〇丁乂^-14及TEM-1等她 
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基因。與162株非^^菌株相比，^^菌株呈高比率的乙內醯胺類/乙內醯胺酶抑制物 
抗藥性、高比率的「低程度」氟化喹諾酮抗藥性及更多與質粒介導的AmpC乙內醯 
胺酶基因並存等現象。有固體型腫瘤病歷記錄及醫院獲得性感染則常見於^^呈陽性 
的病患群中。研究群的整體30天死亡率為27.5% (25/204)，而提供^^菌株的病患 
群其整體30天死亡率則顯著地俨<0.05)更高（47.6%)。多變量Cox迴歸分析發現該 
病患群的高死亡率可能是由於患有肺炎、缺乏合適的抗生素治療及高匹茲堡敗血症評 
分等因素所致。 
總括而言，本研究在血液培養中所獲得的腸桿菌科菌株呈高普遍性的qnr基因 
及多重抗藥性。令人憂慮的是，高程度的氟化喹諾酮抗藥性可能進一步限制治療藥物 
的選擇。再者，這些菌株很可能把^^基因連同办治基因橫向地轉換，並利用質粒快 
速地散播。因此，對於這些抗藥性菌株的連續性監察及其藥敏型式測定，尤其對超廣 
譜乙內醯胺酶及/或質粒介導的AmpC乙內醯胺酶生產者來說是必須的；同時亦須嚴 
格遵從感染控制措施以防止這些抗藥性菌株的散播。 
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Chapter 1 Introduction 
Introduction 
1.1 • Quinolone Antimicrobial Agents 
1.1.1. Development 
Quinolones are synthetic antibiotics. The first quinolone identified was nalidixic 
acid. Nalidixic acid is a by-product of chloroquine synthesis and has a 4-quinolone 
nucleus (Fig. l - la ) . Fluoroquinolone is made by the addition of a fluorine atom at 
position 6 ofthe nucleus (Fig. l - lb ) . Different fluoroquinolones are made from via 
the modifications to the nucleus, these include for example, the addition of an alkyl 
chain to position 1, a -CH3 or -NH2 group to position 5, a piperazinyl group to 
position 7 or a fluorine or chlorine atom to position 8. A l l these modifications in 
fluoroquinolones can lead to an increased spectrum and activity against both Gram-
positive and Gram-negative bacteria. [Ball, 2000; Andersson & MacGowan, 2003; 
Emmerson & Jones, 2003]. 
0 0 
6 ^ V r ^ o H 
H 3 c ^ N ^ N r 2 8 ^ 
、 C H 3 
Figure l - la Chemical structure of nalidixic acid 
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Figure l - l b Chemical structures of several fluoroquinolone molecules 
The quinolones can be classified into three generations (I, Ila，IIb, IIIa and IIIb) 
according to their antibacterial activity [Ball, 2000]. The first generation quinolone 
(QlG), nalidixic acid, was discovered in 1962 [Lesher et al., 1962] is active against 
the Enterobacteriaceae and has only moderate activity against the pseudomonads 
and the Gram-positives. Due to its narrow spectrum of activity, low serum level and 
toxicity, it was mainly used to treat patients with urinary tract infections [Ball, 2000]. 
Other Q lG (pipemidic acid and oxolinic acid) were also shown with the same 
limited clinical applications. Due to its limited usage, the second generation (IIa and 
IIb) quinolone, fluoroquinolone was developed by adding a fluorine atom to position 
C-6 of the nucleus. The generation IIa fluoroquinolone includes ciprofloxacin, 
levofloxacin, lomefloxacin, norfloxacin, ofloxacin and pefloxacin [Ball, 2000; Van 
Bambeke et aL, 2005; Vincent, 2005]. The generation IIa fluoroquinolone has 
increased activity against Pseudomonas aeruginosa but still with limited activity 
2 
Chapter 1 Introduction 
against the Gram-positives. The generation IIb fluoroquinolone (eg. grepafloxacin 
and sparfloxacin) was then developed to increase its activity against Streptococcus 
pneumonia and anaerobes [Ball, 2000; Van Bambeke et aL, 2005; Vincent, 2005]. 
Later on, the generation IIIa fluoroquinolone (eg. gatifloxacin，moxifloxacin, 
trovafloxacin and gemifloxacin) were developed and were found to have enhanced 
activity against Gram-positive pathogens [Ball, 2000; Van Bambeke et aL, 2005]. 
Nowadays, fluoroquinolones can be used to treat various kinds of infections 
including gonococcal infections, ostemyelitis, enteric and respiratory tract infections 
[Van Bambeke et aL, 2005; Vincent et al., 2005]. 
1.1.2. Mode of action 
Quinolones enter bacteria through porins or directly through the lipid and 
cytoplasmic membrane to target DNA topoisomerases [Drlica & Zhao, 1997]. 
Quinolones act by binding to two targets, DNA gyrase (topoisomerase II) and 
topoisornerase IV [Drlica & Zhou, 1997]. DNA gyrase introduces negative 
supercoils into the DNA. It is composed of two GyrA and two GyrB subunits which 
are encoded by gyrA and gyrB genes, respectively [Takiff et aL, 1994; Forsyth et al., 
1995]. Topoisomerase IV is responsible for decatenation or separation of daughter 
chromosomes at the end of a round of replication [Zechiedrich & Cozzarelli，1995]. 
It is also composed of two ParC and two ParE subunits which are encoded by parC 
and parE genes, respectively [Kato et al., 1990]. During replication, complexes are 
formed between the DNA and DNA gyrase or topoisomerase IV. Quinolones bind to 
these complexes to form a quinolone-DNA-enzyme complex and change its 
conformation. These quinolone-DNA-enzyme complex prevent religation of broken 
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DNA strands and inhibit DNA replication. As a result, cell growth is blocked [Drlica 
& Zhao, 1997; Hawkey, 2003; Blondeau, 2004]. 
1.1.3. Mechanisms of resistance to quinolones 
Bacteria can become resistant to quinolones due to one or more of the following 
mechanisms: the accumulation of mutations in target genes that alter the targets of 
quinolones; mutations that reduce intracellular quinolones accumulation by 
upregulation of efflux pump systems either alone or together with decreased 
expression of outer membrane proins; plasmid-mediated quinolone resistance by 
Qnr proteins, amino-glycoside acetyltransferase AAC(6')-Ib-cr and the efflux pump 
QepA [Ince & Hooper，2002; Ruiz, 2003; Hopkins et aL, 2005; Li, 2005; Robicsek 
et aL, 2006a&2006b]. 
1.1.3.1. Target genes mutations 
The targets of quinolone action are DNA gyrase and topoisomerase IV. 
Phenotypic resistance arises in a stepwise fashion as a result of accumulating 
mutations. Mutations in these genes change the structure of the targets and result in 
reduced drug affinity [Hooper, 1999]. Mutations first occur in DNA gyrase (gyrA) 
in Gram-negative bacteria, but they occur first in topoisomerase IV Q?arC) in Gram-
positive bacteria [Jacoby, 2005; Van Bambeke et al, 2005]. Mutations in gyrA are 
mostly found in the so-called quinolone resistance-determining region (QRDR) 
which is between amino acid Ala67 and Glnl06 of gyrA in Escherichia coli 
[Yoshida et al., 1990]. The common mutation points are at codon Ser83 and Asp87 
in the gyrA gene [Oram & Fisher, 1991; Vila et al., 1995; Everett et al., 1996; 
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Heisig, 1996; Tavio et al., 1999; Hopkins et aL, 2005]. A single mutation in gyrA 
reduced quinolone susceptibility to Gram-negative bacteria, additional mutations in 
gyrA and/or inparC can further augment resistance [Jacoby, 2005; Van Bambeke et 
al., 2005]. On the other hand, mutations first occur in parC in Gram-positive 
bacteria (eg. Staphylococcus aureus and Streptococcus pneumoniae). Additional 
mutations were found in gyrA to have a higher level of quinolone resistance pv[g et 
al, 1996; Eliopoulos, 2004]. 
gyrB mutations are less commonly found as compared to gyrA mutations. Few 
cases have been reported in Escherichia coli, Pseudomonas aeruginosa and 
Staphylococcus aureus [Yoshida et aL, 1991; Ito et aL, 1994; Mouneimne et al., 
1999]. Like gyrB mutation, parE mutations are infrequent and are found in high-
level fluoroquinolone-resistant strains that have gyrA and/or parC mutations [Komp 
et aL, 2003; Takahashi et aL, 1998; Eliopoulos, 2004]. 
1.1.3.2. Decreased intracellular quinolone accumulation 
Another mechanism of quinolone resistance is conferred by decreasing 
intracellular quinolone accumulation by the upregulation of efflux pumps either 
alone or together with decreased expression of outer membrane porins. 
There are non-specific, energy-dependent efflux systems in both Gram-negative 
and Gram-positive bacteria. For example, the AcrAB-TolC system is the major 
system involved in the efflux of quinolones in Escherichia coli [Poole, 2004]. Other 
efflux pump systems that exist in Gram-positive bacteria are for example, the NorA 
in Staphylococcus aureus, the PmrA in Streptococcus pneumoniae, the EmeA in 
5 
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Enterococcus faecalis [Gill et al, 1999; Jonas et al., 2001; L i & Nikaido, 2004] and 
the EfrAB in Enterococcus. faecalis [Lee et al., 2003]. 
The second mechanism leading to decreased intracellular quinolone 
accumulation is associated with decreased expression of outer membrane porins. 
Quinolones may cross the outer membrane by specific porins or by diffusion 
through the phosopholipid bilayer [Drica & Zhou, 1997]. Three major outer 
membrane porins, OmpA, OmpC and OmpF, have been characterized in Gram-
negative bacteria. The decrease in expression of the OmpC or OmpF encoding genes 
have been shown in E. coli to decrease the uptake of quinolones [Aoyama et aL, 
1987; Chapman and Georgopapadakou, 1988]. 
1.1.3.3. Plasmid-mediated quinolones resistance 
Three plasmid-mediated quinolone resistance mechanisms have been identified: 
Qnr proteins, the amino-glycoside acetyltransferase AAC(6')-Ib-cr and the efflux 
pump QepA. Qnr proteins wi l l be discussed in more details in section 1.2. 
The amino-glycoside acetyltransferase AAC(6')-Ib-cr was discovered in 
Shanghai, China in 2003 from Escherichia coli [Wang et al, 2003]. It is a variant of 
an amino-glycoside transferase AAC(6')-Ib, which confers resistance to tobramycin, 
amikacin and kanamycin. The AAC(6')-Ib-cr variant differs to AAC(6')-Ib by two 
codon changes, 102 (Trp^>Arg) and 179 (Asp—Tyr)，both substitutions are required 
to reduce the susceptibility to some fluoroquinolones [Robicsek et al, 2006b]. It 
acetylates the unsubstituted piperazinyl group of fluoroquinolones (such as 
ciprofloxacin and norfloxacin), other fluoroquinolones lacking unsubstituted 
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piperazinyl group are unaffected [Robicsek et al., 2006b]. In general, AAC(6')-Ib-cr 
confers low-level resistance to ciprofloxacin and norfloxacin only and the effect on 
minimum inhibitory concentration (MIC) is smaller than that by Qnr proteins 
[Robicsek et al, 2006b]. 
Most of the efflux pumps are chromosome-borne； a novel efflux pump QepA 
(quinolone efflux pump) was identified in Escherichia coli from a urine specimen 
from an inpatient in Japan and Belgium [Yamane et al, 2007; Perichon et al., 2007]. 
QepA is a 51 l-amino-acid protein that belongs to the 14-transmambrane-segment 
(14-TMS) major facilitator superfamily (MFS) of transporters [Yamane et al, 2007; 
Perichon et al., 2007]. It increases the MICs of ciprofloxacin and norfloxacin by 3.2-
and 64-fold respectively in comparison with a wild-type susceptibility profile 
[Yamane et al., 2007]. However, it has no significant effect on the MICs of nalidixic 
acid, perfloxacin, sparofloxacin, levofloxacin and moxifloxacin [Yamane et al., 
2007; Perichon et al, 2007]. Interestingly, other antibiotics (e.g. ampicillin, 
erythromycin, kanamycin and tetracycline) were not effluxed by QepA [Yamane et 
al, 2007; Perichon et al,, 2007]. 
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1.2. Plasmid-mediated Quinolones Resistance Genes (qnr) 
1.2.1. Discovery of qnrA genes 
In 1994，Martinez-Martinez and colleagues at the University of Alabama in 
Birmingham, USA discovered a novel plasmid-mediated quinolone resistance gene 
(qrtr) (GenBank accession number AY070235) from a multidrug-resistant Klebsiella 
pneumoniae from a patient's urine specimen [Martinez-Martinez et aL, 1998]. This 
resistance gene was carried by a 56-kb plasmid, pMG252, that was resistant to 
quinolones, p_lactamams, aminoglycosides, sulphonamides, trimethoprim and 
chloramphenicol. It contains a 657-bp open reading frame and encodes a 218-amino-
acid protein named Qnr, this protein was later renamed as QnrAl , since related 
proteins have since been identified [Martinez-Martinez et al., 1998; Nordmann and 
Poirel, 2005]. 
In 2005, Nordmann and Poirel reported that a variant of qnrA was identified 
from a Klebsiella oxytoca isolate in the Anhui Province, China p^ordmann & Poirel, 
2005]. It differs from the originally detected gene by four amino acids. This variant 
was designated qnrA2 (GenBank accession number AY675584). When Poirel and 
colleagues tried to search qnrA in the genome sequences of environmental 
organisms, they identified three additional variants (qnrA3, qnrA4, and qnrA5) 
(GenBank accession numbers DQ058661, DQ058662, and DQ058663, respectively) 
of this gene in Shewanella algae, that differed from qnrAl from two to four codons 
[Poirel et aL, 2005b]. qnrA3 (GenBank accession number AY906856) was also 
detected in clinical Salmonella enterica and Klebsiella pneumoniae isolates in Hong 
Kong and France respectively [Cheung et aL, 2005; Chu et al.，2006; Cambau et al, 
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2006]. More recently, Cambau and colleagues identified qnrA6 (GenBank accession 
number DQ151889) in a Proteus mirabilis isolate in France [Cambau et al, 2006]. 
1.2.2. Discovery of qnrS genes 
qnrS was first identified from Shigella flexneri 2b that caused a food-borne 
outbreak of enterocolitis in Aichi Prefecture, Japan in 2003 [Hata et al” 2005]. The 
genome of this Shigella flexneri contains an open reading frame encoding a 218-
amino-acid protein of the pentapeptide repeat family and was named QnrS 
(GenBank accession number AB187515). This protein shared only 59% amino acid 
identity with QnrAl and was later renamed as QnrSl. 
While Gay and colleagues was searching for qnr genes among clinical non-
Typhi serotypes of Salmonella isolates in USA, qnrS2 (GenBank accession number 
DQ485530) was identified from Salmonella enterica serovar Anatum. It encoded a 
protein (QnrS2) that is 92.2% identical in amino acid sequence to QnrSl [Gay et al” 
2006]. At the same time, qnrS2 was also identified from a mobilizable IncQ-related 
plasmid (pGNB2) isolated from the activated sludge basin of a wastewater treatment 
plant in Germany [Bonemann et al, 2006]. qnrS3 (GenBank accession number 
EU077611) was identified in a veterinary clinical Escherichia coli isolate in 
Guangdong, China. It differed from qnrSl in one codon. Finally, qnrS4 (GenBank 
accession number FJ418153) [Yue et al, 2008] was identified recently in a 
Salmonella isolate in Denmark [Torpdahl et al., 2009]. 
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1.2.3. Discovery of qnrB genes 
Another qnr gene (qnrBl) (GenBank accession number DQ351241) was 
identified from Klebsiella pneumoniae from India [Jacoby et aL, 2006]. It encoded a 
214 amino acid protein (QnrBl) which shared 43% and 44% amino acid identities 
with QnrA and QnrS, respectively [Jacoby et al., 2006]. qnrB2 (GenBank accession 
number DQ351242) was identified from Citrobacter koseri, Enterobacter cloacae 
and Escherichia coli in USA. It differed from qnrBl in five codon positions [Jacoby 
et aL, 2006], qnrB3 and qnrB4 (GenBank accession numbers DQ303920 and 
DQ303921, respectively) were identified among the ceftazidime-resistant 
Enterobacteriaceae in the USA [Robicsek et aL, 2006c] and qnrB5 (GenBank 
accession number DQ303919) was identified from non-Typhi serotype Salmonella 
enterica isolates in USA [Gay et al, 2006]. They differed from qnrBl in 2, 14, and 
6 codons, respectively. 
Among the other qnrQ variants (qnrB6 to qnrB24), only eight of them have been 
published. qnrB7 and qnrB8 (GenBank accession numbers EU043311 and 
EU043312, respectively) were identified in Enterobacter cloacae and Citrobacter 
freundii respectively in Kuwait City, Kuwait [Cattoir et al, 2007b]. These genes 
differed from qnrBl by 4 and 11 amino acids, respectively. qnrQl0 (GenBank 
accession number DQ631414) was identified in Citrobacter freundii, Enterobacter 
cloacae, Enterobacter aerogenes and Klebsiella pneumoniae in Argentina [Quiroga 
et al., 2007]. It differed from qnrBl by five amino acids. qnrB12 (GenBank 
accession number AM774474) was identified in Citrobacter werkmanii in Germany 
[Kehrenberg et al., 2008]. It differed from qnrBl by eight amino acids. qnrBl3, 
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qnrBl4, and qnrBl5 (GenBank accession numbers ABX72042, ABX72044，and 
ABX72227, respectively) were identified in Citrobacter freundii in South Korea 
[Tamang et al., 2008]. They differed from qrirBl in four, five, and five amino acids, 
respectively. qnrBl9 (GenBank accession number EU432277) was identified in 
Escherichia coli isolate in Colombia [Cattoir et al, 2008a]. It differed from qnrQl 
by six amino acids. 
Sequences of eleven more qnrB alleles have been deposited in GenBank. qnrB6 
(GenBank accession number EF520349) was identified in Escherichia coli in China. 
qrirB9 (GenBank accession number EF526508), qnrB 11 (GenBank accession 
number EF653270) were identified in different isolates of Citrobacter freundii in 
China and France respectively. qrtrBl6 (GenBank accession number EU136183), 
and qnrBl7 and qnrBlS (GenBank accession numbers AM919398 and AM919399, 
respectively) were identified in different isolates of Citrobacter freundii in Spain. 
qrtrB20 (GenBank accession number AB379831), qrirQ2l (GenBank accession 
number FJ611848) were identified in different isolates of Escherichia coli in Japan 
and Ireland respectively. qnrB22 (GenBank accession number FJ981621), and 
qnrB23 (GenBank accession number FJ981622) were identified in South Korea in 
Citrobacter werkmanii and Citrobacter freurtdii respectively. Finally, qnrB24 has 
not been assigned any GenBank accession number yet. 
1.2.4. Discovery of qnrC genes 
In 2009, qnrCl (GenBank accession number EU917444) was identified in a 
Proteus mirabilis isolate from Shanghai, China which transferred low-level 
quinolone resistance [Wang et al, 2009]. This 666-bp gene, which was carried by 
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plasmid pHS9 encoded a 221-amino-acid protein QnrC. It shared 64%, 41%, 59%, 
and 43% amino acid identities with QnrAl , QnrBl, QnrSl, and QnrD, respectively. 
1.2.5. Discovery of qnrD genes 
In 2009, qnrD (GenBank accession number EU692908) was identified in four 
Salmonella enterica isolates in the Henan Province ofChina [Cavaco et al., 2009]. It 
was carried by a small plasmid of 4270bp and encoded a 214-amino-acid protein, 
which shared 48%, 61% and 41% similarity to qnrAl, qnrBl and qnrSl respectively. 
1.2.6. Origins of qnr genes 
Scientists hypothesized that qnr genes were originated on the chromosome ofan 
organism in a human, veterinary, or environmental reservoir. They tried to find out 
the source of these qnr genes and fmally found that the origin of qnr gene was the 
aquatic environment [Poirel et al, 2005a; Poirel et al, 2005b; Loscol et al, 2008; 
Saga et aL, 2005; Venter et al, 2004; Sanchez et al., 2008; Cattoir et a/.,2007c; 
Bonemann et al, 2006; Picao et al., 2008; Cattoir et aL, 2008b]. 
Poirel and colleagues reported that three qnrA variants (qnrA3 to qnrA5) were 
identified in the chromosome of Shewanella algae [Poirel et aL，2005b]. In addition, 
Lascol and colleagues found that the sequence immediately downstream from qnrA3 
was identical to the DNA sequence in the Shewanella algae chromosome [Loscol et 
aL, 2008]. This finding suggested that the qnrA3 gene has been excised from the 
chromosomal DNA of Shewanella algae or similar organisms [Loscol et al, 2008]. 
Shewanella algae is widely distributed in both marine and freshwater environments. 
In addition, other previous reports have shown that some pentapeptide repeat 
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proteins had 57% to 67% amino acid identity with QnrA in other waterborne species, 
including Vibrio vulnificus, Vibrio parahaemolyticus, and Photobacterim profundum 
[Poirel et al, 2005a; Saga et aL, 2005]. 
The origin of qnrB was also found in the aquatic environment. Venter, Sanchez 
and colleagues found that marine metagene Qnr (GenBank accession number 
ACY020347520) in microbial populations collected en masse from seawater 
samples in the Sargasso Sea [Yenter et al., 2004; Sanchez et aL, 2008]. This 
metagene Qnr was 88% similar to QnrB5 and QnrB19. Besides, it was 98% similar 
to qnrB8, and the first 214 amino acids were 99% identical to QnrB8. 
Consistently, the origin of qnrS was also found in aquatic environment. Firstly, 
Cattoir and colleagues found that chromosomal-encoded Qnr proteins in Vibrio 
splendidus shared 84% and 88% amino acid identity to QnrSl and QnrS2 
respectively [Cattoir et a/.,2007c]. Secondly, Bonemann and colleagues also found 
qnrS2 plasmids in sludge basin bacteria isolated from the activated sludge basin of a 
wastewater treatment plant in Germany [Bonemann et al, 2006]. Thirdly, qnrS2 was 
also found in plasmids from Aeromonas allosaccharophila in Lake Lugano (a 
Swiss-Italian vacation area) [Picao et al., 2008]. In addition, qnrS2 was also found 
in plasmids from Aeromonas punctata subsp. punctata and Aeromonas media in 
water from urban sites in the Seine river in 2006 [Cattoir et al., 2008b]. Finally, 
other previous reports showed that some pentapeptide repeat proteins in other 
waterborne species, including Vibrio vulnificus, Vibrio parahaemolyticus, and 
Photobacterim profundum showed 52% to 62% amino acid identity to qnrS [Poirel 
et al, 2005a; Saga et aL, 2005]. 
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In conclusion, all these findings suggested that the aquatic environment was the 
reservoir for qnr genes and that qnr genes may have been originated from the 
chromosomes of water-dwelling environmental organisms. Scientists believed that 
quinolones are excreted by human into the wastewater and accumulated in aquatic 
environment [Robicsek et al., 2006a]. With the presence of quinolone pressure, such 
qnr genes have entered into the aquatic organisms by mobile genetic elements to 
provide a survival advantage. Therefore, qnr genes would be maintained in aquatic 
organisms i f quinolone accumulation persists in aquatic environment. 
1.2.7. Qnr proteins and mode of action 
qnr gene encodes a Qnr protein that belongs to the pentapeptide repeat family. 
Qnr proteins are made oftandemly repeated amino acid sequences with the recurrent 
motif [Ser, Thr, Ala, or Val][Asp or Asn][Leu or Phe][Ser, Thr, or Arg][Gly] 
[Vetting et aL, 2006]. Nowadays, more than 500 pentapeptide repeat proteins are 
known in prokaryotes and eukaryotes [Vetting et aL, 2006]. However, the function 
of these proteins still remains unknown. Two pentapeptide repeat proteins (McbG 
and MfpA) are of particular interest because they also confer some level of 
quinolone resistance. 
McbG is a pentapeptide repeat protein that shares 19.6% amino acid identity 
with QnrA. It protects the DNA gyrase against the effect of microcin [Garrido et al, 
1988]. One ofthe microcin, microcin B17 (MccB17) inhibits DNA gyrase [Heddle 
et al, 2001]. In the host Escherichia coli J53 cells, plasmid-mediated mcbG slightly 
increased the MIC ofsparfloxacin but did not affect the susceptibility ofEscherichia 
coli J53 to ciprofloxacin or nalidixic acid [Strahilevitz et al, 2009]. 
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MfpA is another pentapeptide repeat protein encoded by the chromosome of 
Mycobacterium smegmatis and shares 18.9% amino acid identity with QnrA 
[Montero et al, 2001]. A multi-copy plasmid encoding MfpA increased the MIC of 
ciprofloxacin by four-fold and the inactivation of the gene on the Mycobacterium 
smegmatis chromosome increased ciprofloxacin susceptibility [Montero etal., 2001]. 
Based on these data, it was proposed that MfpA mimics DNA and binds to and 
inhibits DNA gyrase which resulted in the increased resistance in some 
fluoroquinolones [Hegde etal,, 2005]. 
The detailed mechanism ofthe Qnr protein action is still unknown. Qnr proteins 
do not modify the intracellular quinolone accumulation and outer membrane porins, 
or inactivate quinolones [Tran & Jacoby，2002]. QnrA protects and reduces DNA 
gyrase from quinolones like MfpA [Tran et al., 2005a]. Tran and colleagues reported 
that QnrAl was able to bind to both DNA gyrase (GyrA and GyrB) and 
toposiomerase IV (ParC and ParE) subunits that do not require the presence of the 
ternary complex of enzyme, DNA, or quinolone [Tran et al., 2005a; Tran et al, 
2005b]. However, unlike MfpA, QnrA does not affect the supercoiling of DNA 
[Tran & Jacoby, 2002; Hegde et al, 2005]. Based on these findings，it was proposed 
that QnrA confers quinolone resistance by binding to DNA gyrase or topoisomerase 
IV at a site overlapping the DNA binding site. However, it is not clear how, in vitro, 
QnrA binds to DNA gyrase without functionally inhibiting its activity. 
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1-2.8. Epidemiology and quinolones resistance activity 
of qnr genes 
Qnr determinants (qnrA, qnrB and qnrS) have been identified worldwide in 
many Enterobacteriaceae, especially in Klebsiella pneumoniae, Enterobacter spp., 
Escherichia coli, and Salmonella enterica, from among community and nosocomial 
isolates [Martinez-Martinez et al., 1998; Jacoby et al, 2006; Jacoby et al, 2003; 
Rodriguez-Martinez et al, 2003; Gay et al., 2006; Poirel et al, 2006; Pai et al” 
2007; Xu et al” 2007; Cheung et al, 2005; Chu et al, 2006; Cattoir et al” 2007b; 
Park et al” 2007; Wu et al., 2007; Wang et al., 2008]. Their overall prevalence 
ranged from 0.2% to 87%, depending on the criteria used in strain selection (e.g. 
resistance to ceftazidime, to nalidixic acid, to fluoroquinolones or produce extended-
spectrum p-lactamase (ESBL) or that associated with AmpC genes). More 
importantly, a high prevalence rate of qnr gene was found among multidrug-
resistant Enterobacteriaceae isolates in recent years. For instance, it was reported 
that 23% o f ceftazidime-resistant Klebsiella pneumoniae, Enterobacter spp. and 
Escherichia coli harbored the qnr genes (mostly among the ESBL producers) in the 
USA [Robicsek et al, 2006c]. In United Kingdom, the prevalence of qnr gene was 
32% among the ciprofloxacin- and cefotaxime-resistant Enterobacteriaceae blood-
cultured isolates [Corkill et al, 2005]. In Korea, 38.4% and 28.5% of AmpC P-
lactamase producing Citrobacter freundii and Enterobacter cloacae carried the qnr 
genes respectively [Park et al., 2007]. In China, a nationwide study (including 
Beijing, Tianjin, Shenyang, Jinan, Shanghai, Wuhan, Nanjing, Guangzhou and 
Fuzhou) reported that the prevalence rate of qnr gene was 38.5% among 
Enterobacteriaceae with MICs of ciprofloxacin greater than or equal to 0.25 vagfL 
1 6 
Chapter 1 Introduction 
[Yang et al” 2008]. Little data about Qnr determinants exists in Hong Kong. Cheung 
and colleagues identified qnrA in Salmonella enterica [Cheung et aL, 2005]. They 
also identified qnrA3 in Salmonella enterica which were intermediately resistant to 
ciprofloxacin [Chu et al” 2006]. However, none of the quinolone-resistant 
Escherichia coli harboured qnrA gene [Chu et al, 2008]. 
The qnr genes are responsible for resistance to first generation quinolones (such 
as nalidixic acid) but not to fluoroquinolones according to CLSI breakpoints [Hata et 
al, 2005; Hu et al., 2008; Jacoby et al, 2006; Wang et al, 2004b]. In fact, qnr 
genes are responsible for ‘low-level，quinolone resistance. The presence of qnr-
positive plasmid increased quinolone MICs of ciprofloxacin, levofloxacin and 
moxifloxacin by 16 to 33 times. However, a lesser increase (4 times) was found in 
MIC of nalidixic acid [Hata et al, 2005; Hu et al., 2008; Jacoby et al, 2006; Wang 
et al., 2004b]. Although qnr genes caused ‘low-level' quinolone resistance, studies 
have shown that they could facilitate the selection of higher level of resistance 
[Martinez-Martinez et al” 1998; Martinez-Martinez et al, 2003; Poirel et al, 2006]. 
Once ^wr-positive strains have developed fluoroquinolone resistance, they may 
threaten the efficacy of fluoroquinolones therapy. Moreover, previous studies have 
shown that qnr genes may be associated with ESBL or AmpC genes which may 
further limit the therapeutic choice for patients infected with ^wr-positive isolates. 
1.2.9. Epidemiology of fluoroquinolone-resistant 
Enterobacteriaceae 
Fluoroquinolones are used widely for the treatment of serious Escherichia coli 
urinary tract infections and fluoroquinolone resistance in Enterobacteriaceae may 
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lead to treatment failures. According to the 2004 NNIS report, about 7.3% and 8.2% 
of Escherichia coli isolates were resistance to fluoroquinolones from US patients in 
both ICUs and non-ICU areas of hospitals respectively psfNIS, 2004]. Also, about 
3.6% of Escherichia coli isolates from US outpatient were resistance to 
fluoroquinolones psfNIS, 2004]. In addition, surveillance data from European 
Antimicrobial Resistance Surveillance System (EARSS) showed that 
fluoroquinolone resistance has increased significantly across the whole of Europe 
since 2001，with levels ranging from 7% (Estonia and Norway) to 53% (Turkey) in 
2007 [EARSS]. Overall, only 47% of Escherichia coli were susceptible to four 
classes of antibiotics in Europe in 2007, with the loss of susceptibility occurring 
more rapidly to fluoroquinolones than to any other antibiotic class included in the 
EARSS surveillance database [EARSS]. Furthermore, in a multicenter study in 
China including Beijing, Guangzhou, Hong Kong, Hunan, Shanghai, Wuhan and 
Zhejiang showed that about 50.6% and 25.2% of Escherichia coli and Klebsiella spp. 
were resistance to ciprofloxacin respectively [Ling et al., 2006]. 
Higher rates of fluoroquinolone resistance may be found in extended-spectrum 
p-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae. For 
example, 55.8% of infections caused by ESBL-producing Escherichia coli or 
Klebsiella pneumoniae were fluoroquinolone resistant in the University of 
Pennsylvania Health System [Lautenbach et al, 2001]. Besides, 86.1% and 45.6% 
of ESBL-producing Escherichia coli and Klebsiella pneumoniae were reported to be 
resistant to levofloxacin respectively [Xiong et al, 2002]. In addition, Paterson 
found that 18% of bacteraemic ESBL-producing Klebsiella pneumoniae isolates 
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were ciprofloxacin resistant and 60% of bacteraemic ciprofloxacin-resistant 
Klebsiella pneumonia isolates produced ESBLs [Paterson et al, 2000]. 
1.2.10. Multidrug-resistant in extended-spectrum p-
lactamase- and AmpC-producing 
Enterobacteriaceae 
Nowadays, there are more than 180 TEM type, 130 SHV type, 100 CTX-M type 
and 80 AmpC type p-lactamases found in Gram-negative bacilli 
rhttp://www.lahev.org/StudiesA). ESBL producing Enterobacteriaceae were resistant to 
all cephalosporins and extended spectrum penicillins including the monobactam, 
aztreonam, trimethoprim/sulphamethaxazole and aminoglycosides. Also, high rates 
of fluoroquinolone resistance may be found in ESBL-producing Enterobacteriaceae 
[Lautenbach et al, 2001; Xiong et al, 2002 & & Paterson et al, 2000]. ESBLs were 
usually susceptible to p-lactam/p-lactamase inhibitor combinations, but the efficacy 
of these drugs may be reduced by large amounts of enzymes that produced by 
bacterial isolates [Varsha Gupta, 2007]. ESBLs were also susceptible to 
cephamycins such as cefoxitin and cefotetan. However, extensive use ofcephamycin 
therapy may promote the occurrence of AmpC-producing Enterobacteriaceae 
[Varsha Gupta, 2007]. AmpC-producing Enterobacteriaceae were resistant to 
cephalosporins and were not inhibited by clavulanic acid. Most studies showed that 
carbapenems is the most effective antibiotics to treat both ESBL- and AmpC-
producing Enterobacteriaceae [Kang et al,, 2004; Reinert et aI., 2007]. 
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1.3. Background of Study 
^wr-harboring organisms have been identified in many parts of the world, but 
data is sparse in Asian countries, including Hong Kong. In Hong Kong, so far only 
Cheung and his colleagues reported qnrA gene in Salmonella enterica but the 
prevalence of qnrA gene in other Enterobacteriaceae species, and the presence of 
the qnrB and the qnrS genes in bacteria present in Hong Kong still remain unknown 
[Cheung et la” 2005]. In addition, earlier studies have revealed that qnr genes might 
be associated or linked to the ESBL genes and the plasmid-mediated AmpC 
(PMAmpC) genes, but little data exists in this regard in Hong Kong. Furthermore, 
the clinical significance of qnr genes and clinical outcomes of infection caused by 
^wr-harboring organisms has not been described previously. It is hoped that by this 
study, a better understanding of the prevalence and significance of plasmid-mediated 
quinolone resistance genes in seriously i l l hospitalized patients in Hong Kong can be 
obtained. Such knowledge wil l have important implications on the clinical 
management, surveillance of antibiotic resistance, and may provide guidance on the 
control of its dissemination. 
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1.4. Objectives of Study 
(i) To determine the prevalance of qnr genes in both ESBL- and 
PMAmpC-producing Enterobacteriaceae in bacteraemic patients; 
(ii) To determine the impact of qnr genes on the antimicrobial 
susceptibilites against these selected Enterobateriaceae； 
(iii) To study the association of qnr genes with other bacterial resistance 
genotypes ^ S B L and PMAmpC genes); and 
(iv) To study the association of qnr genes with the clinical characteristics 
and outcomes of patients, 
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Materials & Methods 
2.1. Study Design 
A total o f 950 Enterobacteriaceae isolates {Escherichia coli N = 575, 
Klebsiella spp. N = 236, Enterobacter spp. N = 53, Proteus spp. N = 50, Citrobacter 
spp. N ^ 19, Serratia spp. N 口 14 and Salmonella spp. N = 3) which were isolated 
from blood samples of consecutive adult patients (aged 18 or above) with 
bacteraemia in the clinical microbiology laboratory between Jan 2008 to Apr 2009 at 
the Prince of Wales Hospital, Hong Kong were collected real-time. Only the first 
episode of each patient during this period was included in this study. These isolates 
were screened for the production of ESBL and AmpC p-lactamase using standard 
microbiological methods according to Clinical and Laboratory Standards Institute 
(CLSI) standards and confirmed by multiplex PCR. 
Subsequently, a total of 204 cases were recruited prospectively and the 
corresponding isolates that produced ESBL and/or AmpC p-lactamase were stored 
on nutrient agar fKA) (Oxoid, Basingstoke, England) slants at ambient temperature 
and in glycerol broth at -20°C for further study. Bacteria were recovered from 
storage by subculturing on MacConkey agar (Oxoid, Basingstoke, England). The 
antimicrobial susceptibility results by disk diffusion test of all isolates were obtained 
prospectively by microbiology laboratory reports. 
A l l 204 isolates were selected for further testing: MICs against quinolones 
(ciprofloxacin, fleroxacin, moxifloxacin, nalidixic acid, norfloxacin and levofloxacin) 
were determined by microbroth dilution method according to CLSI standard [CLSI 
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2008]; and qnr genes were detected using multiplex PCR. Al l ^r-positive isolates 
were sequenced and characterized. The blajEu, blasm, blacjx-M and blaAmpc genes of 
all ^wr-positive isolates were also sequenced and characterized. The sequences were 
blast online using BLAST (http://blast.ncbi.nlm.nih.gov/) and compared with the 
sequences online (http://www.lahey.org/qnrStudies/ and http://www.lahey.org/Studies/). 
Patient's demographics, clinical data including past medical history, medical 
treatment, previous exposure to antibiotic, current disease severity and antibiotics 
regimen were collected prospectively and thoroughly from patients' clinical records, 
charts and electronic clinical management system (CMS). The major clinical 
outcome in this study was survival status, which was calculated as the mortality rate 
within 30 days after the onset of bacteraemia. Ethical approval for study was 
obtained from the Institutional Review Boards of the Hospital Authority of Hong 
Kong and The Chinese University of Hong Kong. Al l data were analyzed to study 
the associations of qnr genes with all clinical characteristics of patients by Pearson 
Chi-square test or Fisher's Exact test for categorical variables and Student's t test for 
continuous variables. A l l factors that were found to have significance levels of 
P<0.1 in univariate analysis were put into a backward, stepwise multivariate logistic 
regression model (SPSS 18 software, SPSS, IL, USA). The associations of mortality 
with all clinical characteristics of patients were also studied by using Chi-square test 
for categorical variables and Student's t test for continuous variables. Al l factors that 
were found to have significance levels of P<0.1 in univariate analysis were put into 
a multivariate Cox regression model (SPSS 18 software, SPSS, IL, USA) for 
survival analysis. 
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2.2. Antimicrobial Susceptibility Testing 
2.2.1. Bacterial isolates 
A l l 950 Enterobacteriaceae isolates {Escherichia c o / / N = 575，Klebsiella spp. N 
= 2 3 6 , Enterobacter spp. N = 53, Proteus spp. N = 50, Citrobacter spp. N = 19, 
Serratia spp. N = 14 and Salmonella spp. N = 3) which were isolated from blood 
samples of consecutive adult patients (aged 18 or above) with bacteraemia in the 
clinical microbiology laboratory between Jan 2008 to Apr 2009 at the Prince of 
Wales Hospital, Hong Kong were collected real-time. Only the first episode ofeach 
patient during this period was included in this study. A l l these bacteraemic 
Enterobacteriaceae isolates were screened for ESBL and AmpC production as 
described in section 2.2.2 and the positive isolates were stored on nutrient agar slant 
at room temperature and in glycerol broth at -70°C for further study. Standard 
strains of Escherichia coli ATCC 25922, ATCC 35218 and Klebsiella pneumonia 
ATCC 700603 were used as control strains in ESBL screening and antimicrobial 
susceptibility testing. 
2.2.2. Screening for ESBL and AmpC production by disk 
diffusion test 
Commercially prepared antibiotic disks were applied to the surface ofa Mueller-
Hinton (MH) agar (Oxoid, Basingstoke, UK) plate that had been inoculated with a 
bacterial suspension. The inoculum was prepared by inoculating overnight colonies 
in sterile saiine to a turbidity matching that of a MacFarland 0.5 standard (equivalent 
to bacterial concentration of approximately 1.5 x 108 cfu/mL). The bacteria 
suspension was spread evenly on the agar surface using a sterile cotton swab. Paper 
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disks containing ceftazidime (CAZ) (30 ^ig) (Oxoid) and cefotaxime (CTX) (30 p,g) 
(Oxoid) with or without clavulanic acid (10 ^tg) (Oxoid) were placed in the plate 
with a 20 mm distance from other disk for screening the production ofESBL [CLSI 
2008]. Paper disks containing cefoxitin (FOX) (30 p,g) (Oxoid) was placed on 
another plate for screening the production of AmpC p-lactamase. A 5 mm increase 
in a zone diameter of either CAZ or CTX with clavulanic acid versus its zone 
without clavulanic acid was considered as an ESBL-producing isolate. While an 
AmpC p-lactamase-producing isolate was considered positive with zone diameter of 
FOX disk less than 18 mm. The agar plates were incubated overnight at 37。C and 
zone diameters were measured. 
2.2,3. Determination of minimal inhibitory 
concentrations (MICs) 
Minimal inhibitory concentrations (MICs) were determined by microbroth 
dilution method [CLSI, 2008]. Cation-adjusted M H broth (Oxoid, Basingstoke, UK) 
containing serial two-fold dilutions of antibiotics were prepared (Table 2-1). Each 
bacterial strain to be tested was inoculated in 2.0 mL Brain Heart Infusion (BHI) 
broth (Oxoid, Basingstoke, UK) and incubated for 4 hours to late log phase. The 
bacterial concentration was adjusted in sterile 0.9% saline to a turbidity matching 
that of a MacFarland 0.5 standard, diluted 10-fold and used as the inoculum. MIC-
2000 inoculator (Dynatech Laboratories, Inc., California, USA) was used to deliver 
approximately 2.25xl04 colony forming units onto antibiotic-containing plates. The 
agar plates were incubated at 37。C for 18 hours. A strain was regarded as resistant to 
an antibiotic when MIC was greater than the breakpoint for susceptible strains 
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according to CLSI standards [CLSI 2008]. The concentration of antimicrobial agents 
that inhibited growth of 50% and 90% of the isolates, MIC50 and MIC90 respectively, 
was calculated. The Chi-square test (SPSS 18 software, SPSS, IL, USA) was used to 
calculate the difference in resistance rates. A l l P values were 2-tailed, and a P value 
of less than 0.05 was considered to be statistically significant. 
Table 2-1: Antibiotics and range of concentration tested 
^.,. A. Range of concentration 0 Antibiotic & , „ � Source (mg^L) 
〜 ot . A M " Bayer Yukuhin Ltd. 
Ciprofloxacin 0.03-64 Osaka, Japan 
口 . n n a a o Sigma, Chemical Co., 
Fleroxacm u.u3 - 32 M〇 USA 
1, .r, . A M “ Bayer Yukuhin Ltd. 
M0x1fl0xacm 0.03-64 Osaka, Japan 
XT r , . . . , n n . . , Sigma, Chemical Co., 
Nalidixic acid 0.06 — 64 M o USA 
. Sigma, Chemical Co., 
Norfloxacin 0.03 - 64 MQ uSA 
^ . . ._ ^ . Daiichi Pharmaceutical Co. Ltd., 
Levofloxacm 0-03 - 64 Tokyo, Japan 
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2.3. Detection of qnrA, qnrB and qnrS Genes by Multiplex 
PCR 
The presence of qnrA, qnrB and qnrS genes were detected by multiplex PCR 
using specific primers for qnrA, qnrB and qnrS genes (Table 2-2). 
2.3.1. Total DNA preparation 
Bacterial strains were grown overnight at 37°C on M H agar plate (Oxoid, 
Basingstoke, UK). One loopful of bacteria were scraped from the surface of the M H 
agar plates and emulsified in 0.5 mL sterile double distilled water in an eppendorf 
tube. The bacterial emulsion was centrifuged at 6010 x g for 5 minutes in a micro-
centrifuge (Centrifuge 5424, Eppendorf, Germany). The supernatant was discarded 
and the cell pellet was resuspended in 0.5 mL sterile double distilled water. The 
suspension was incubated for 5 minutes in boiling water (~100°C) and was 
centrifuged for 5 minutes at 6010 x g. The aqueous phase (DNA) was then 
transferred to a fresh eppendorf tube and stored at 4°C for future usage. 
2.3.2. Multiplex PCR assay for qnrA, qnrB and qnrS 
genes detection 
DNA was extracted as described above and was used as template for PCR. 
Three pairs of oligonucleotide primers (Invitrogen, Oregon, USA) were used. 
Primers QnrA-F and QnrA-R are specific for qnrA gene, primers QnrB-F and QnrB-
R are specific for qnrB gene, and primers QnrS-F and QnrS-R are specific for qnrS 
gene. Different qnr genes can be identified by different sizes of the amplified DNA 
fragments. Primers used for amplification of qnrA, qnrB and qnrS genes and their 
product sizes are shown in Table 2-2. 
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Amplification reactions were carried out in a thermal cycler (GeneAmp PCR system 
9700，Applied Biosystems, Foster City, USA) in 25 ^tL reaction volume, each 
containing 1.25 unit Taq polymerase (TaqGold，Applied Biosystems, Foster City, 
USA), l x PCR reaction buffer (10 mM Tris-HCl，pH=8.3, 50 m M KC1), 1.5 m M 
MgCl2 (Applied Biosystems, Foster City, USA), 0.2 m M each of the 
deoxynucleoside triphosphates (dNTP) (Applied Biosystems, Foster City, USA), 0.4 
jaM each of the six primers and 2 ^L of template DNA. PCR was performed at 95°C 
for 5 minutes, 35 cycles each at 95°C for 1 minute, 63°C for 1 minute and 72°C for 
1 minute and a final extention at 72°C for 10 minutes [Cattoir et al., 2007b], 
Table 2-2: Oligonucleotide primers used for amplification of qnrA, qnrB and 
qnrS genes and their product sizes 
Primer Nucleotide Sequence Product Size (bp) Reference 
QnrA- F 5'- AGAGGATTTCTCACGCCAGG - 3 ' 
580 
QnrA- R 5'- TGCCAGGCACAGATCTTGAC - 3 ' 
QnrB- F 5'- GGMATHGAAATTCGCCACTGa - 3 ' 
„ . Cattoir et al., 
264 b 
QnrB- R 5'- TTTGCYGYYCGCCAGTCGAAa-3' 
QnrS- F 5'- GCAAGTTCATTGAACAGGGT - 3 ' 
428 
QnrS- R 5'- TCTAAACCGTCGAGTTCGGCG - 3 ' 
a M = A or C; H = A or C or T; Y = C or T 
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2.3.3. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to confirm the size of the PCR product. 
Two grams of Seakem LE® agarose power (Cambrex Bio Science, Rockland, USA) 
was dissolved in 100mL boiling IX Tris-borate-EDTA (TBE) buffer (Cambrex Bio 
Seience, Rockland, USA) and 2 ^L SYBR® safe stain (Molecular probes, 
Invitrogen, Oregon, USA) was added into the agarose gel mixture for pre-staining. 
Five microlitres ofPCR product was mixed with 1 jaL 6x loading buffer (0.25 % 
bromophenol blue and 15 % Ficoll type 400) and loaded into the wells of an agarose 
gel immersed in TBE buffer inside a gel tank. Electrophoretic separation was 
performed at 100V for 1 hour. The PCR product bands were visualized and 
photographed under ultraviolet illumination using a gel documentation system 
Chemidoc™ XRS system (Bio-Rad, Philadelphia, USA). 
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2.4. Detection of TEM-, SHV-, CTX- and PMAmpC Type p-
Lactamase Genes by PCR 
TEM, SHV and CTX-M p-lactamases are three common types o f ESBL in 
many parts of the world and thus in this study the presence o fTEM, SHV and CTX-
M genes were detected by PCR using specific primers were shown in Table 2-3. 
AmpC cephalosporinases are chromosomally encoded in some Enterobacteriaceae 
{Citrobacter spp., Enterobacter spp., Serratia spp.) but PMAmpC genes were found 
and able to transfer b la \ m c gene to other bacteria lacking or poorly expressing 
chromosomal blap^c gene, such as Escherichia coli, Klebsiella pneumonia and 
Proteus mirabilis. PMAmpC genes were detected by using other specific primers 
(Table 2-3). 
In all PCR assays (detection of TEM, SHV, CTX and PMAmpC genes), 
DNA was prepared as described in section 2.3.1. Two microliters of template DNA 
were amplified in a 25-jaL reaction mix containing 0.2 m M each of dNTP (Applied 
Biosystems, Foster City, USA), l x PCR reaction buffer, 1.5 m M MgCl2 (Applied 
Biosystems，Foster City, USA), 1.25 unit Taq polymerase (TaqGold, Applied 
Biosystems, Foster City, USA) and 0.2 ^- 1.0 p,M of each primer. The PCR were 
performed at 95°C for 5 minutes, 35 cycles each at 95°C for 30 seconds, annealing 
at 550C - 68°C for 30 seconds and 72°C for 1 minute and a final extension step at 
720C for 10 minutes was given to each PCR. Primer concentrations, the annealing 
temperatures of all detection PCR and their product sizes were shown in Table 2-3. 
Different bla genes can be identified by different sizes of the amplified DNA 
fragments. Agarose gel was prepared and agrose gel electrophoresis was carried out 
as described in section 2.3.3. 
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2-5. PCR Assays for Further Genotypic Characterization 
Purpose 
qnrB and qnrS genes were detected in 42 isolates. These 42 霄-positive 
isolates were selected for further characterization by sequencing method. The co-
existed blajEM, blasuv, blacix-u and blaAmpc genes of these 42 ^wr-positive isolates 
were also sequenced and characterized. 
In all PCR assays, DNA was prepared as described in section 2.3.1. Two 
microliters of template DNA were amplified in a 25-^L reaction mix containing 0.2 
mM each of dNTP (Applied Biosystems, Foster City, USA), l x PCR reaction buffer, 
1.5 mM MgCl2 (Applied Biosystems, Foster City, USA), 1.25 unit Taq polymerase 
(TaqGold, Applied Biosystems, Foster City, USA) and 1 ^ tM of each primer. 
The cycling PCR conditions were the same in all PCR assays except for the 
amplification of qnrB genes and wil l be discussed in section 2.5.1. The PCR was 
performed at 95°C for 5 minutes, 35 cycles each at 95°C for 30 seconds, annealing 
at 55°C for 30 seconds and 72°C for 1 minute and a final extension step at 72°C for 
10 minutes was given to each PCR except for the amplification of qnrB genes. Al l 
specific primers were shown in Table 2-4. Agarose gel was prepared and agrose gel 
electrophoresis was carried out as described in section 2.3.3. A l l PCR products were 
then subsequently sequenced. 
2.5.1. PCR assay to amplify qnrB genes 
Al l ^wrB-positive isolates were amplified by another specific primer QnrB-469-
F and QnrB-469-R (Table 2-4) to produce longer nucleotide products (469bp) for 
further characterization of qnrB variants. The PCR assay was same as described in 
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section 2.5 except the cycling PCR conditions. The PCR was performed at 95°C for 
5 minutes, 32 cycles each at 94°C for 45 seconds, 53°C for 45 seconds and 72°C for 
1 minute and finally at 72°C for 10 minutes [Robicsek et al.’ 2006c]. 
2.5.2. PCR assay to amplify qnrS genes 
Al l ^r^rS-positive isolates were amplified by using another specific primer QnrS-
622-F and QnrS-622-R (Table 2-4) to produce longer nucleotide products (622bp) 
for forther characterization of qnrS variants [Lavilla et al., 2008]. 
2.5.3. PCR assays for genotypic characterizations of the 
co-existed b/aTEM,to/aSHV，fc/aCTX_Mand PMAmpC 
genes of all qnr-positive isolates 
2.5.3.1. Genotypic characterizations of the co-existed 
b/aTEM and Jb/aSHV genes 
The blajEM and blasnv genes of all gwr-positive isolates were further 
characterized by directly sequencing the amplified PCR products in section 2.4. 
2.5.3.2. PCR assays to amplify the co-existed blaCjx-M 
genes 
As it was difficult to characterize CTX-M variants of all gwr-positive isolates in 
one assay, four different PCR assays were used. Firstly，CTX-M group 9 genes were 
detected in 10 gwr-positive isolates and another specific primers (Table 2-4) were 
used to amplified whole CTX-M group 9 genes (870bp) for further characterization 
of CTX-M variants by sequencing [Ho et aL, 2005]. Secondly, CTX-M group 1 
genes were detected in 10 gnr-positive isolates and another specific primers (Table 
2-4) were used to amplified whole CTX-M group 1 genes (876bp) for further 
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characterization of CTX-M variants by sequencing [Batchelor et al., 2005]. However, 
it was still difficult to characterize all CTX-M variants by sequencing the above 
PCR products (870bp and 876bp) because two CTX-M variants (CTX-M-14 and 
CTX-M-18) which belong to CTX-M group 9, have identical amino acid sequences. 
Another two CTX-M variants (CTX-M-55 and CTX-M-57), which belong to CTX-
M group 1 have identical amino acid sequences. Therefore, two other PCR assays 
were used for the detection of the upstream insertion sequence (lSEcpl) in order to 
differentiate these four CTX-M variants, as CTX-M-14 and CTX-M-57 contain the 
upstream insertion sequence (lSEcpl) whereas CTX-M-18 and CTX-M-55 do not. 
As 10 CTX-M group 9-positive isolates harbored either CTX-M-14 or CTX-M-18, 
so PCR assay was used to differentiate CTX-M-14 and CTX-M-18 for these 10 
CTX-M group 9-positive isolates by specific primer (Table 2-4) [Ho et aL, 2005]. 
Only one CTX-M group l-positive isolate harbored either CTX-M-55 or CTX-M-57, 
so PCR assay was used to differentiate CTX-M-55 and CTX-M-57 for this CTX-M 
group l-positive isolate by specific primer (Table 2-4). 
2.5.3.3. PCR assay to amplify the co-existed PMAmpC 
genes 
The PMAmpC genes of all ^wr-positive isolates were directly sequenced using 
the amplified PCR products in section 2.4 except for the positive isolates for primer 
pair CITMF and CITMR. Another PCR assay was used to amplify full-length CITM 
PCR amplicon was generated with primers CITM-Full-F and CITM-Full-R (Table 
2-4) for characterization ofPMAmpC genes [Perez-Perez and Hanson, 2002]. 
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Table 2-4: Primers used for amplification of qnrB, qnrS, blacrx-M an^ 
PMAmpC genes of all ^rwr-positive isolates for genotypic characterization 
Primer Target Nucleotide Sequence 二： (二）Reference 
QnrB-469-F 5'- GATCGTGAAAGCCAGAAAGG -3' 
n .^„ Robicsek et 
—B 469 aL, 2006c 
QnrB-469-R 5'-ACGATGCCTGGTAGTTGTCC -3' 
QnrS-622-F 5'- CCTACAATCATACATATCGGC -3' 
c ^ 0 0 Lavilla et 
—S 622 aL, 2008 
QnrS-622-R 5'- GCTTCGAGAATCAGTTCTTGC -3' 
M9U-F „ n , 5'- ATGGTGACAAAGAGAGTGCA -3' 
Whole u „ , 
CTX-M 870 H 0 : f ； 
M9Ll-R g r ° U p 5'- CCCTTCGGCGATGATTCTC -3' 
CTX-M-1 5'-ATGGTTAAAAAATCACTGCG -3' 
group-F 
二 , « 7 , Batchelor 
C T X � 8 7 6 eta/ . ,2005 
group 1 
CTX-M-1 5'-TTACAAACCGTCGGTGAC -3' 
group-R 
ISEcplUl-F Upstream 5'- AAAAATGATTGAAAGGTGGT -3' 
ISEcpJ of Q O S Ho et aL, 
CTX-M 2005 
MA2-R group 9 5'- CCGCRATATGRTTGGTGGTR -3' 
ISEcplUl-F 5'- AAAAATGATTGAAAGGTGGT -3' 
Upstream Modified 
^ H 0 / 1036 f romHoe/ 
CTX-M , 2 0 Q 5 
CTX-M-1 group 1 5'-TTACAAACCGTCGGTGAC -3' .， 
group-R 
CITM-Full-F 5'- AACACACTGATTGCGTCTGAC -3' Perez-Perez 
Whole 1 2 2 6 二 
CITM Hanson, 
CITM-Full-R 5'- CTGGGCCTCATCGTCAGTTA -3' 2002 
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2.5.4. Sequencing reaction 
2.5.4.1. Purification of PCR product and sequence 
determination 
Approximately 20 ^tL ofPCR products were purified by PCRquick-spin ™ PCR 
product purification kit (iNtRon Biotechnology, Inc., Seongnam, Kyunggi, Korea) to 
remove primers, unreacted dNTP and salts. PCR products was first bound to the 
purification column by adding 500 juJL binding buffer into the column and incubated 
for 1 minute and then centrifuged at 15871 x g for 1 minute. The column was then 
washed with 700 ^iL washing buffer and centrifuged at 15871 x g for 1 minute. The 
purified PCR product was eluted out by adding 30 ^L sterile water and centrifuged 
at 15871 x g for 1 minute. A l l purified PCR products were then sent to l s tBASE 
Laboratories for DNA sequence determination by the fluorescence-labeled 
dideoxynucleotide approach using ABI BigDye® Terminator Sequencing kit v3.0 
(Applied Biosystems, Foster City, USA). The fluorescence-labeled PCR product 
was then purified with DyeEx® (Qiagen，hilden, Germany) and was loaded with Hi-
D i™ formamide (Applied Biosystems, Foster City, USA). The sequences were 
generated with an AB I 3100 genetic analyzer (Applied Biosystems, Foster City, 
USA). The sequencing results were exported from the analyzer and stored as AB1 
files by AB I DNA sequencing analysis software v5.2 (Applied Biosystems, Foster 
City, USA). AB1 files that contain the sequencing chromatogram and the nucleotide 
sequence in text codes were used for further sequence analysis. 
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2.5.4.2. Sequence analysis 
Nucleotide sequences were blast online using BLAST 
(http ://blast.ncbi.nlm.mh. gov/) and compared with the sequences online 
(http://www.lahey.orgy^qnrStudies/ and http ://www.lahey.org/StudiesO using Bioedit 
version 7.0 available at http://www.mbio.ncsu.edu/BioEdit^ioedit.htmL 
http://www.lahey,org/qnrStudies/ is a website for sequence alignment of qnr genes and 
http://www.lahev,org/Studies/ is a website for sequence alignment of bla genes for 
TEM, SHV, CTX-M and AmpC. 
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2.6. Collection of Clinical Data 
2.6.1. Demographics and clinical data 
Demographics (age and sex) and clinical data including past medical history/co-
existing diseases (cancer, liver cirrhosis, end stage of renal failure, diabetes mellitus, 
human immunodeficiency virus (HIV) infection and congestive heart failure), 
currently immunosuppressive treatment, history of medical treatment (prior 
hospitalization, invasive procedures and prior antibiotic exposure), source of 
bacteraemic infection, current disease severity, current ICU admission, current 
antibiotic regimen and survival states were collected prospectively from patients' 
clinical records, charts and electronic clinical management system (CMS). 
2.6.2. Definitions 
Bacteraemia was defined as the presence of bacteria in one or more blood 
cultures. Onset of bacteraemia was defined as the date when the first positive blood 
culture was obtained. 
Patient was considered as under immunosuppressive treatment i f steroid therapy 
was used during the onset of bacteraemia and/or chemotherapy, radiotherapy within 
14 days prior to the onset ofbacteraemia. 
Hostel was defined as any healthcare associated institutes including elderly 
hostels or any long-term care institutes. 
Prior hospitalization was defined as any inpatient treatment in the 12 months 
prior to admission. 
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Invasive procedure was defined as any surgery, insertion of central venous 
catheters or indwelling urinary catheters, percutaneous transhepatic biliary drainage 
(PTBD) within 30 days prior to the onset ofbacteraemia. 
Other catheter was defined as urinary catheter such as foley, Tenkoff and any 
catheters for guided drainage or aspiration. 
Previous positive ESBL infection was defined as any ESBL positive isolate was 
identified in any kinds of specimen by routine screening in the clinical microbiology 
laboratory prior one year before the onset ofbacteraemia. 
Prior exposure to antibiotics was defined as administration of any oral or 
parenteral antimicrobial agents for >3 days during 30 days prior to the onset of 
bacteraemia. 
Hospital-acquired infection was defined as bacteraemia documented 48 hours or 
more after hospital admission. 
Site of infection leading to bacteraemia was determined as urinary tract infection, 
hepatobiliary tract infection, intra-abdominal infection, pneumonia and others. Site 
of infection was based on positive culture in patients' specimen such as urine, bile, 
CAPD fluid, peritoneal fluid, sputum and aspirates from respiratory tract with the 
same organism isolated from patients' blood samples, together with compatible 
manifestations as suggested by clinical and radiographic studies (such as 
radiographic pneumonia). 
Severity of illness at the time of onset of bacteraemia was quantified by the Pitt 
bacteraemia score as follows: temperature of>38°C, (1 point), temperature of>39°C, 
(2 points), mental status (alert, 0 points; disorientated, 1 point; stupor, 2 points, 
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coma, 4 points), hypotension (2 points), mechanical respiratory support (2 points), 
and cardiac arrest (4 points). Hypotension was defined as a systolic pressure of less 
than 90mmHg. Patients were considered i l l at a level of 4+ i f they accumulated four 
or more points [Korvick et al, 1992, Chow & Yu, 1999]. 
The empirical antibiotics treatment was defined as administration of any oral or 
parenteral antimicrobial agents between the date of blood culture collection and the 
issue date ofblood culture report. The definitive antibiotics treatment was defined as 
administration of any oral or parenteral antimicrobial agents for >3 days after the 
issue date ofblood culture report. 
30-day mortality was defined as all cause mortality that occurred during the 
same hospital stay and within 30 days after onset ofbacteremia. 
2.6.3. Data analysis 
Statistical analysis was conducted using SPSS 18 (SPSS 18 software, SPSS, IL, 
USA). Categorical data were analyzed by Pearson Chi-square test or Fisher's Exact 
test and continuous variables were analyzed by Student's t test to identify possible 
factors that were associated with the presence of qnr genes. A l l P values were 2-
tailed, and a P value of less than 0.05 was considered to be statistically significant. 
A l l factors that were found to have significance levels of P<0.1 in univariate 
analysis were put into a backward, stepwise multivariate logistic regression model. 
Only factors that reached statistical significance ofP<0.05 were included in the final 
model. The level of significance was defined at >95% level. 
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Results 
3.1. Bacterial Isolates 
A total o f 950 Enterobacteriaceae isolates {Escherichia coli N = 575, 
Klebsiella spp. N 二 236, Enterobacter spp. N 二 53，Proteus spp. N = 50, Citrobacter 
spp. N = 19, Serratia spp. N = 14 and Salmonella spp. N = 3) were isolated from 
blood samples of consecutive adult patients (age 18 or above) with bacteraemia in 
the clinical microbiology laboratories between Jan 2008 and Apr 2009 at the Prince 
of Wales Hospital, Hong Kong. One hundred and fifty three (16.1%) isolates 
produced ESBL alone, 16 (1.7%) isolates produced PMAmpC alone and 35 (3.7%) 
isolates produced both p-lactamases. The distribution of 204 ESBL- and/or 
PMAmpC-producers are shown in Table 3-1, most of them were Escherichia coli 
and Klebsiella spp (Table 3-1). The prevalence of ESBL in bacteraemic 
Enterobacteriaceae was 19.8% (188/950). The prevalence of ESBL in Escherichia 
coli and Klebsiella spp. were 24.7% (142/575) and 10.2 % (24/236) respectively. 
The prevalence ofPMAmpC in bacteraemic Enterobacteriaceae was 5.4% (51/950). 
The prevalences of PMAmpC in Escherichia coli and Klebsiella spp. were 2.6% 
(15/575) and 8.5% (20/236) respectively 
Table 3-1: The Distribution of204 ESBL- and PMAmpC- producing isolates 
. Escherichia Klebsiella Citrobacter Enterobacter Serratia 
Organism ^ sp^ sp^ sp^ spp. 
No. 146 36 4 15 3 
% 7L6 \Jj6 2 l_A_ 1.5 
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3.2. Demographics, Medical History, Clinical Features and 
Clinical Outcomes of Patients 
A total of 204 patients with bacteraemia due to ESBL- and/or PMAmpC-
producing Enterobacteriaceae were prospectively enrolled. The demographics, co-
morbidities, clinical features and clinical outcomes of these patients were shown in 
Table 3-2. 
Fifty-five percent of patients were female. The mean age was 69.3 土 17.0 
years. 142 (69.6%) of patients had a history of co-morbidities that we studied, in 
which 62 (30.4%) patients had solid tumour and 57 (27,9%) patients had diabetes. 
Forty-nine (24.0%) patients lived in hostel; 174 (85.3%) patients had prior 
hospitalization within one year before the onset of bacteraemia; 104 (51.0%) 
patients had history of catheters insertion. A total of 113 (55.4%) patients had 
previous exposure to antibiotics treatment. Most of them (43.1%) received 
penicillins, 20.1% received cephalosporins and 14.2% received fluoroquinolones. 
About 40.7% of patient's infection were hospital-acquired. About half of the 
bacteraemic cases (46.6%) were associated with urinary tract infection and 27.9% 
were associated with hepatobiliary and intra-abdominal infection. A total of 34 
(16.7%) patients required intensive care at the onset of bacteraemia and the mean 
Pitt bacteraemia score was 2.5 士 2,3. 37 (19.9%) patients with Pitt bacteaemia score 
greater than or equal to four and were classified as severely ill. The 30-day mortality 
rate was 27.5%. 
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Table 3-2: The demographics, medical history, clinical features and 
clinical outcomes of 204 patients 
Characteristic No. / mean 士 SD % 
Demgraphic 
Female 113 55.4 
Age 69.3 ± 17.0 
Co-morbidities and clinical features 
With one of the following co-morbidities 142 69.6 
Solid tumour 62 30.4 
Hematological malignancy 12 5.9 
Immunosupressive treatment 26 12.7 
Diabetes 57 27.9 
Liver cirrhorsis 15 7.4 
Heat failure 14 6.9 
End stage of renal failure 12 5.9 
HIV 0 0 
Live in hostel 49 24 
Hospital stay prior one year 174 85.3 
Invasive procedure prior one month 74 36.3 
IV catheter or other catheter prior one month 104 51.0 
Previous positive ESBL 55 27.0 
With one of the following antibiotics prior one month 113 55.4 
Penicillins 88 43.1 
Cephalosporins 41 20.1 
Fluoroquinolones 29 14.2 
Carbapenems 11 5.4 
Aminoglycosides 9 4.4 
Macrolides 5 5.0 
Others antibiotics 30 14.7 
Hospital-acquired infection ^ Q^ ^ 
Source of bacteraemia 
Uurinary tract infection 95 46.6 
Hepatobiliary tract infection and intra-abdominal infection 57 27.9 
Pneumonia 29 14.2 
Others infection 23 11.3 
ICU stay in this admission 34 16.7 
Pitt bacteraemia score 2.5 土 2.3 
Pitt bacteraemia score > 4 37 19.9 
Clinical outcomes 
30-day mortality 56 27.5 
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3.3. Antimicrobial Susceptibility Testing 
The antimicrobial resistance rates of all 204 isolates to antibiotics by disk 
diffusion test are shown in Table 3-3, the MICs and antimicrobial resistance rates of 
six quinolones by microbroth dilution method are shown in Table 3-4. 
In Table 3-3, all strains were susceptible to imipenem and were resistant to 
ampicillin. The resistance rate of cefuroxime (94.6%) was the highest, followed by 
cefotaxime (87.7%), amoxicillin/clavulanate (66.2%) and 
sulfamethoxazole/trimethoprim (60.8%). Among ESBL-producing strains, the 
resistance rates of cephalosporins (ceftazidime, cefepime, cefotaxime and 
cefuroxime) were high, ranged from 25.5% to 96.8%. The resistance rates of P-
lactam/p-lactamase inhibitor (BLBLI) (amoxicilli^clavulanate, 
cefoperazone/sulbactam and piperacillin/tazobactam) were also high, ranged from 
14.4% to 63.8%. The resistance rate of sulfamethoxazole/trimethoprim was 63.8% 
and the resistance rates of aminoglycosides (gentamicin and amikacin) ranged from 
9.6% to 48.4%. Among PMAmpC-producing strains, the resistance rate of 
amoxicillin/clavulanate was high (96.1%), followed by cefuroxime (86.3%), 
cefotaxime (60.8%), sulfamethoxazole/trimethoprim (52.9%) and ceftazidime 
(49.0%). Most ofthem remained susceptible to cefepime, amikacin and imipenem. 
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Table 3-3: Antimicrobial resistance rates of all 204 isolates by 
disk diffusion method 
Antibiotic No. of isolates % of resistance (%) 
All isolates (N=204) 
Ampicillin 204 100 
Imipenem 0 0 
Amikacin 18 8.8 
Gentamicin 94 46.1 
Ceftazidime 54 26.5 
Cefepime 51 25.0 
Cefotaxime 179 87.7 
Cefuroxime 193 94.6 
Amoxicillin/clavulanate 135 66.2 
Cefoperazone/sulbactam 54 26.5 
PiperacillinAazobactam 32 15.7 
Sulfamethoxazole/trimethoprim 124 60.8 
ESBL-producers (N=188) 
Ampicillin 188 100 
Imipenem 0 0 
Amikacin 18 9.6 
Gentamicin 91 48.4 
Ceftazidime 48 25.5 
Cefepime 51 27.1 
Cefotaxime 173 92 
Cefuroxime 182 948 
Amoxicillin/clavulanate 120 63.8 
Cefoperazone/sulbactam 50 26.6 
Piperacillin/tazobactam 27 14.4 
Sulfamethoxazole/trimethoprim 120 63.8 
PMAmpC-producers (N=51) 
Ampicillin 51 100 
Imipenem 0 0 
Amikacin 3 5.9 
Gentamicin 13 25.5 
Ceftazidime 25 49.0 
Cefepime 4 7.8 
Cefotaxime 31 60.8 
Cefuroxime 44 86.3 
AmoxicillhVclavulanate 49 96.1 
Cefoperazone/sulbactam 11 21.6 
Piperacillin/tazobactam 19 37.3 
Sulfamethoxazole/ tr imethoprim 27 52.9 
45 
Chapter 3 Results 
The MICs and antimicrobial resistance rates of six quinolones were shown in 
Table 3-4. The resistance rates of nalidixic acid, ciprofloxacin, fleroxacin, 
levofloxacin, moxifloxacin and norfloxacin in these 204 isolates were 74.0%, 55.9%, 
52.5%, 51.0%, 52.0% and 55.4% respectively. The MIC50 and MIC90 of all isolates 
were greater than or equal to 4 mgyL and 32mg/L respectively. A total of 157 
(76.9%) isolates among these 204 isolates were resistant to any one of the 
quinolones and 116 (56.9%) isolates were resistant to one or more quinolones. 
Among ESBL-producing isolates, the resistance rates of quinolones ranged from 
54.3% to 78.7%. 114 (60.6%) isolates among all ESBL-positive isolates were 
resistant to one or more quinolones. For PMAmpC-producing isolates, the resistance 
rates of quinolones ranged from 39.2% to 51.0%. 
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Table 3-4: Antimicrobial resistance rates of all 204 isolates against 
quinolones by microbroth dilution method 
~ MIC (mg/L) No. 
A n t i b i o t i c Range MICS0 MIC90~~ (%ofR) 
All isolates (N=204) 
Nalidixic acid l ->64 >64 >64 151 (74.0) 
Ciprofloxacin 0.03->64 4 64 114(55.9) 
Fleroxacin 0.03->32 8 >32 107 (52.5) 
Levofloxacin 0.03->64 4 32 104(51.0) 
Moxifloxacin 0.03->64 4 32 106 (52.0) 
Norfloxacin 0.03 - >64 16 >64 113(55.4) 
ESBL-producers (N=188) 
Nalidixicacid l ->64 >64 >64 148(78.7) 
Ciprofloxacin <0.03 - >64 8 >64 102 (54.3) 
Fleroxacin <0.03 - >32 16 >32 105(55.9) 
Levofloxacin <0.03->64 4 64 102 (54.3) 
Moxifloxacin <0.03 - >64 8 64 104(55.¾ 
Norfloxacin <0.03->64 32 >64 111 (59.¾ 
PMAmpC-producers (N=51) 
Nalidixic acid l ->64 64 >64 26 (51.0) 
Ciprofloxacin <0.03->64 1 >64 25 (49.0) 
Fleroxacin <0.03->32 2 >32 20(39.2) 
Levofloxacin <0.03->64 1 32 20(39.2) 
Moxifloxacin <0.03->64 2 32 20 (39.2) 
Norfloxacin <0.03->64 2 >64 25 (49.0) 
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3.4. Detection of qnr Genes 
3.4.1. Detection of qnrA, qnrB and qnrS genes by 
multiplex PCR 
Al l 204 ESBL- and/or PMAmpC-producers were screened for the presence of 
qnr genes. A total of 42 (20.6%) isolates harbored qnr genes. Twenty-six (12.8%) 
isolates produced 264 bp fragment after amplification using primers in (QnrB-F and 
QnrB-R in Table 2-2), indicating the presence of qnrB gene (Figure 3-1). Sixteen 
(7.8%) isolates produced 428 bp fragment after amplification using primers in 
(QnrS-F and QnrS-R in Table 2-2), indicating the presence of qnrS gene (Figure 3-
1). None ofthe isolates produced 580bp fragment after amplification using primers 
in (QnrA-F and QnrA-R in Table 2-2), indicating the absence of qnrA gene (Figure 
3-1). Among these 42 qnr-positb/Q isolates, 34 (80.9%) isolates were Klebsiella spp., 
4 (9.5%) isolates were Escherichia coli, 2 (4.8%) isolates were Citrobacter spp. and 
2 (4.8%) isolates were Enterobacter spp. 
B ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ S 
^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ 5^ 1 ^ f . < ^ ^ ^,^, i “卞：.:>，'-j ！辦‘ ‘；i ^ i . 
^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^&^^ ^^ ^S^^ ^^ ^^ ^^ ^^ ^^ l^ 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 1 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 1 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ ^ P I » ^ S - 1 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
I I 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
^ ^ ' ^ ¾ ¾ - ¾ & * - ^ ^ ^ ^ - ? ½ ¾ 二麗 ^ 600bp 
隆 ^ ^ 禱 玄 ^ ^ 键 餘 漆 绍 書 蒸 縛 二 ^ 500 bp 
^ ^ ^ ^ ^ ^ ¾ & ¾ ¾ • - & # 3 ¾ ¾ ^ ^ ^ V ^ < - 400bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
^ ^ ^ ¾ ^ ¾ ! ^ & % ^ - ' - ^ ^ t t S ^ f 5 ¾ H < 300bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M ^ | ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ ^ ^ ^ ^ ^ ^ ^ ^ ¾ ¾ : ¾ ¾ ¾ ¾ ¾ ¾ ^ . ¾ 4 200 bp • .. . 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^S^^^a^aaiSS888SgjjiSS;ggsyBB=^S<*sysg^R=f^w*Jgsw^wTtwynrm 
Figure 3-1 Amplification oiqnrA, qnrB and qnrS gene by specific primers 
Lane Lane 
~T : qnrA, positive control, 580bp 5 : ECOL ATCC 25922, negative control 
2 ： qnrB, positive control, 264bp 6 : Reagent control, negative control 
3 ： Clinical specimen contains qnrB M : 100bp marker 
4 : qnrS, positive control, 428 bp 
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3.5. Detection of ESBLs 
3.5.1 • Detection of TEM- and SHV-type ESBLs 
Al l 188 ESBL-producing isolates were screened for the presence of ^/^iEM,and 
blasm genes. A total of 120 (63.8%) isolates and 35 (18.6%) isolates produced 1074 
bp fragment and 865 bp fragment respectively after amplification using primers 
TEM-F and TEM-R, SHV-S-F and SHV-AS-R in Table 2-3，indicating the presence 
ofZ?/«TEMand Z>/aSHvgenes respectively (Figure 3-2，Figure 3-3). 
• S i l 
創 纖 _ 
^ B I 
i H W i 
f ^ S B S W 8 ^ 
^ ^ ^ ^ ^ ^ ^ ^ H 一 _ _ J M M M -
600b5 ——!<———— 
500bp • B " ! i ! 册 B i B i — i M M — 
^ f e a m a a < ^ S i M M i ^ M ^ l M M M ^ i f ^ S H ^ ^ i 
- ‘ ‘ T . , - „ U / ' : 、 - '"""••' V ' - - V . ' / . W K . ? d 
m 0 ¾ - ' - _ ,y:',:SW ：； -^">： M _ 3 m 
I • 一 释 望 。 
Figure 3-2 Amplification ofthe 1074 bp fragments by TEM-specific primers. 
Lane 
M : 100bpmarker 
1 ： TEM-1, positive control 
2 : TEM-3, positive control 
3 : TEM-26, positive control 
4 : SHV-2, negative control 
5 : ECOL ATCC 25922, negative control 
6 : Reagent control, negative control 
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W"W^^^^^^M 
i ^ i - - ; < ^ r ^ ^ - • "^fe^^^^^^H 
• . : : . . . . . . . . . . . : : 、 _ 
I 9oobP : g = r g v-;;,v,: v c i & ' i r ^ 
700bp • M M M W M M M M M B M — l i B B i i W I 
6oobp — > g g ^ g g g g g m m j g g m i m m [ u ^ ^ j j 
500bp — • ^ ^ ^ ^ ^ ^ ^ y _ j ^ ^ p ^ ^ ^ 
^ : : ::..• : . A ^ ^ ^ ^ ^ ^ ^ H 
Figure 3-3 Amplification ofthe 865 bp fragments by SHV-specific primers. 
Lane 
M : 100bp marker 
1 : ECOL ATCC 25922, negative control 
2 : Reagent control, negative control 
3 ： Clinical specimen contains SHV 
4 ： Clinical specimen contains SHV 
5 ： TEM-3, negative control 
6 : SHV-2, positive control 
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3.5.2. Detection of CTX-M- type ESBLs 
A l l 188 ESBL-producing isolates were screened for the presence of blacix-M 
genes. ^/aCTx-Mgenes were divided into 4 different groups (group 1，group 2，group 
8，25/26 and group 9) by using specific primers listed in Table 2-3. Isolates with bla 
gene for CTX-M-group 1，CTX-M-group 2, CTX-M-group 8，25/26 and CTX-M_ 
group 9 produced 260 bp, 341 bp , 207 bp and 293 bp fragments respectively 
(Figure 3-4). A total of 149 (79.3%) isolates harbored blacix-u genes. 112 (59.6%) 
isolates harbored CTX-M-group 9 gene, 34 (18.1%) isolates harbored CTX-M-group 
1 gene and 3 (1.6%) isolates harbored both CTX-M-group 9 and CTX-M-group 1 
genes. 
|
陶 
_ 育 : 嗜 涉 . 翁 等 I 
： & € 9 fiEB m m . « » 肩 
K K K K B ^ ^ ^ ^ ^ | 
I H H H ^ = ; 
J ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ g ^ — — 3 0 0 b p 
I ^ ~ " 2°0bP 
^ ^ M ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ P ^ ^ ^ ^ ^ ^ ^ M 
R i f : S 5 : r : ; . ‘:'• ):?:'::¾:,:;::.¾&¾ ^~~ ioobp I 
^SSf:fc&, ： : . . ¾ ; ¾ & ^ ^ ¾ ' & ' : ¾ ¾ 
^ ^ & ^ / •  "" -'-;-¾- ••••••'• -'；^---； :,..r^ 
l ^ ^ : d . . , 、 . n • .一一—」 . .，’ : 
Figure 3-4 Amplification ofthe blaCTX-M genes by specific primers 
Lane Lane 
~ Y ~ . CTXM-2 (group 2)，positive control, 341 bp 5 : ECOL ATCC 25922, negative control 
2 • CTXM-8 (group8,25/26), positive control, 207bp 6 : CTXM-14 (group 9), positive control, 293bp 
3 ; CTXM-9 (group 9)，positive control, 293bp 7 : Reagent control, negative control 
4 ; CTXM-15 (group 1), positive control, 260bp M : 100bp marker 
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3.6. Detection of PMAmpC Genes 
3.6.1. Detection of PMAmpC genes 
Al l 51 PMAmpC-producing isolates were screened for the presence of bla^xc 
genes. blaAmpc genes were divided into six different groups (MOX, CIT, DHA, ACC, 
EBC，FOX) by using specific primers listed in Table 2-3. Isolates with MOX-, CIT-, 
DHA-, ACC-, EBC-, FOX- type ofblaAmPc genes, produced 520 bp, 462 bp，405 bp, 
346 bp, 302 bp and 190 bp fragment respectively (Figure 3-5). A total of 51 isolates 
harbored blaAmpc genes in which 28 (54.9%) isolates harbored DHA-type blaAmpc 
genes, 12 (23.5%) isolates harbored EBC-type blaAmpc genes and 11 (21.6%) 
isolates harbored CIT-type blaAmpc genes. 
m 
Figure 3-5 Amplification ofthe blaAmvC genes by specific primers 
Lane L ^ e 
M : 100bp marker 6 : MIR-1, positive control, 302bp 
1 ： Bil-1, positive control, 462bp 7 : FOX-4, positive control, 190bp 
2 ： CMY-2, positive control, 462bp 8 : ECOL ATCC 25922, negative control 
3 ： DHA-1，positive control, 405bp 9 : Reagent control, negative control 
4 ： ACC-1, positive control, 346bp M : 100bp marker 
5 : ACT-1, positive control, 302bp 
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3.7. The Distribution of qnr and bla Genes for TEM, SHV, 
CTX-M and PMAmpC 
The distribution ofqnr and &/agenes of204 isolates was shown in Table 3-5. 
A total of 42 (20.6%) isolates harbored qnr genes. The genotypes of ^wr-positive 
isolates and the co-existed bla genes wil l be discussed in more details in section 
3.8.1. 
Table 3-5: The distribution ofqnr genes and bla genes in 204 clinical isolates 
qnr gene 
bla genes ^ no qnr gene 
° qnrB qnrS 
TEM + SHV+ PMAmpC 7 
SHV+ CTX-M +PMAmpC 5 
SHV + PMAmpC 5 
PMAmpC 4 12 
CTX-M +PMAmpC 2 
TEM + SHV+ CTX-M + PMAmpC 1 
TEM + PMAmpC 1 1 0 
TEM + SHV 1 1 1 
TEM + SHV+ CTX-M 1 2 
TEM + CTX-M 3 79 
SHV 3 1 
CTX-M 2 4 7 
TEM 4 
TEM + CTX-M + PMAmpC 1 
TEM + SHV + PMAmpC 1 
non-Tem, non-SHV，non-CTX-M 4 
TOTAL 26 16 162 
A total of 162 isolates did not harbor qnr genes. The most common 
genotypes (79 isolates, 48.8%) was bla genes for TEM and CTX-M, followed by (47 
isolates, 29.0%) CTX-M group and (12 isolates, 7.4%) PMAmpC. A total of 94 
(58.0%) isolates harbored more than one type of bla genes and 4 (2.5%) isolates 
harbored bla genes for non-TEM，non-SHV and non-CTX-M. 
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3.8. The Characteristics of qnr Isolates 
3.8.1. Genotypes of qnrB and qnrS 
Al l 26 ^wrB-positive isolates were amplified by other specific primer QnrB-469-
F and QnrB-469-R (Table 2-4) to produce longer nucleotide fragments (469 bp) for 
characterization of qnrB variants. The DNA sequences of all these PCR products 
were determined. A total of23 (88.5%) out of26 ^rB-posit ive isolates were qnrB4, 
1 (3.8%) isolate was positive for the qnrQS gene and 2 (7.7%) isolates were positive 
either for the qnrB6 or qnrB9 genes, qnr6 and qnrB9 could not be distinguished in 
this 469 bp fragment because they differed by only one amino acid in the gene 
sequence that was not amplified by this PCR. 
A l l 16 ^rS-posit ive isolates were amplified by using specific primer QnrS-622-
F and QnrS-622-R (Table 2-4) to produce longer nucleotide fragments (622 bp) for 
characterization of qnrS variants. The DNA sequences of all these PCR products 
were determined. A l l 16 ^wrS-positive isolates were qnrSl. 
The distribution ofthe bla genes in gnr-positive isolates are shown in Table 3-6 
and Table 3-7. Among 26 gwrB-positive isolates, seven (26.9%) isolates co-existed 
with bla genes for TEM-1，SHV and DHA-1, 5 (19.2%) isolates co-existed with bla 
genes for SHV, CTX-M-14 and DHA-1, 5 (19.2%) isolates co-existed with bla 
genes for SHV and DHA-1, 4 (15.4%) isolates co-existed with bla genes for DHA-1 
or CMY, 2 (7.7%) isolates co-existed with bla genes for CTX-M-14, DHA-1 or 
CMY, 1 (3.8%) isolate co-existed with bla genes for TEM-1, SHV-1, CTX-M-15 
and DHA-1, 1 (3.8%) isolate co-existed with bla genes for TEM-1 and DHA-1, 1 
5 4 
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(3.8%) isolate co-existed with bla genes for TEM-1, SHV-1, CTX-M-15 and DHA-1, 
1 (3.8%) isolate co-existed with bla genes for TEM-1 and SHV-1. Two isolates may 
harbor new variants of CMY-type blaAmpC gene, as their DNA sequences did not 
match with all known sequences that available in GenBank and further 
investigations wi l l be followed. 
Among 16 ^wS-positive isolates, seven (43.8%) isolates co-existed with bla 
genes for TEM-1, SHV and CTX-M, 4 (25.0%) isolates co-existed with bla genes 
for TEM-1 and CTX-M, 3 (18.8%) isolates co-existed with bla genes for SHV, 1 
(6.3%) isolate co-existed with bla genes for TEM-1 and SHV-11, 1 (6.3%) isolate 
co-existed with bla genes for CTX-M-3. None of the gwrS-positive isolates co-
existed with bla genes for DHA-1 or CIT. 
5 5 
C
ha
pt
er
 3
 
R
es
ul
ts
 
T
ab
le
 3
-6
: T
he
 g
en
ot
yp
es
 o
ib
la
 
ge
ne
s 
of
26
 ^
rB
-p
os
it
iv
e 
is
ol
at
es
 
N
um
be
ro
f 
G
en
et
yp
es
 o
f 
G
en
ot
yp
es
 
N
=
L
tL
°f
 
O
rg
an
ism
 
iso
la
te
s (
%
) 
bl
a 
ge
ne
s 
Q
nr
B4
 +
 T
EM
-1
 +
 S
H
V
-1
 +
 D
H
A
-1
 
3 
2K
PN
E 
+ 
1 
K
LE
B
 
7 
(1
6 
9)
 
TE
M
 +
 S
HV
 +
 P
M
A
m
pC
 
Q
nr
B4
 +
 T
EM
-1
 +
 S
H
V
-1
1 
+ 
D
H
A
-1
 
^ 
二
= 
K
 
)  
Q
nr
B4
 +
 T
EM
-1
 +
 S
H
V
-3
1 
+ 
D
H
A
-1
 
1 
1
K
P
N
E 
Q
nr
B4
 +
 S
H
V
-1
1 
+ 
CT
X
-M
-1
4 
+ 
D
H
A
-1
 
2 
2K
PN
E 
5(
19
 2
) 
SH
V
 +
 C
TX
-M
 +
 P
M
A
m
pC
 
Q
nr
B4
 +
 S
H
V
-1
2 
+ 
CT
X
-M
-1
4 
+ 
D
H
A
-I 
2  
^
^ 
U
 
;  
Q
nr
B4
 +
 S
H
V
-1
 +
 C
TX
-M
-1
4 
+ 
D
H
A
-1
 
1 
1
K
P
N
E 
Q
nr
B4
 +
 S
H
V
-l
l+
D
H
A
-l
 
4 
4K
PN
E 
5 
(1
9.
2)
 
SH
V
 +
 P
M
A
m
pC
 
Q
n
rB
4 
+ 
SH
V
-3
1+
D
H
A
-1
 
1 
lK
PN
E 
Q
nr
B4
 +
 D
H
A
-l 
“ 
3 
2K
PN
E
+l
E
C
O
L 
4(
15
.4
) 
PM
A
m
pC
 
Q
nr
B8
 +
 C
M
Y
 
J 
lC
IT
R
 
“ 
Q
nr
B6
/B
9 
+ 
CT
X
-M
-1
4 
+ 
D
H
A
-1
 
1 
1
E
C
O
L 
2 
(7
.7
) 
CT
X
-M
 +
 P
M
A
m
pC
 
^
6
4 
+ 
CT
X
-M
-1
4 
+C
M
Y
 
1 
lC
FR
E 
1 
(3
.8
) 
TE
M
 +
 S
H
V
 +
 C
TX
-M
 +
 P
M
A
m
pC
 
Q
nr
B4
 +
 T
EM
-1
 +
 S
H
V
-1
 +
 C
TX
-M
-1
5 
+ 
D
H
A
-1
 
1 
1 
K
PN
E 
1(
3.
8)
 
TE
M
 +
 P
M
A
m
pC
 
Q
nr
B4
 +
 T
EM
-l
+D
H
A
-l 
1 
lE
N
TE
 
1 
(3
.8
) 
TE
M
 +
 S
H
V
 
Q
nr
B6
/B
9 
+ 
TE
M
-1
 +
 S
H
V
-1
 
1 
lK
PN
E 
CF
RE
: C
itr
ob
ac
te
rf
eu
nd
ii;
 C
IT
R:
 C
itr
ob
ac
te
r s
pp
.; 
EN
TE
: E
nt
er
ob
ac
te
r s
pp
.; 
EC
O
L:
 E
sc
he
ri
ch
ia
 c
ol
i; 
K
PN
E:
 K
le
bs
ie
lla
pn
eu
m
on
ia
e;
 K
LE
B:
 K
le
bs
ie
lla
 sp
p.
 
5
6 
C
ha
pt
er
 3
 
R
es
ul
ts
 
T
ab
le
 3
-7
: T
he
 g
en
ot
yp
es
 o
f b
la
 g
en
es
 o
f 
16
 ^
rS
-p
os
it
iv
e 
is
ol
at
es
 
N
um
be
r o
f 
G
en
e t
yp
es
 o
f 
G
en
ot
vD
es
 
N
yn
^^
r 
of
 
O
rg
an
ism
 
iso
la
te
s (
%
) 
to
ge
ne
s 
“
一
 
^
1
^ 
Q
nr
Sl
 +
 T
EM
-1
 +
 S
H
V
-3
3 
+ 
CT
X
-M
-3
 
2 
2K
PN
E~
~ 
Q
nr
S 
1 
+ 
TE
M
-1
 +
 S
H
V
-1
1 
+ 
CT
X
-M
-3
 
2 
2 
K
PN
E 
7 
(4
3 
8)
 
TE
M
 +
SH
V
 +
 C
TX
-M
 
Q
nr
S 
1 
+ 
TE
M
-1
 +
 S
H
V
-6
5 
+ 
CT
X
-M
-3
 
1 
1 
K
PN
E 
Q
nr
Sl
 +
 T
EM
-1
 +
 S
H
V
-2
7 
+ 
CT
X
-M
-1
4 
1 
lK
PN
E 
Q
nr
Sl
 +
 T
EM
-1
 +
 S
H
V
-1
1 
+ 
CT
X
-M
-1
4 
1 
1 
K
PN
E 
Q
nr
S 
1 
+ 
TE
M
-1
 +
 C
TX
-M
-3
 
2 
2 
K
PN
E 
4(
25
.0
) 
TE
M
 +
 C
TX
-M
 
Q
nr
Sl
 +
 T
EM
-1
 +
 C
TX
-M
-1
4 
1 
lE
A
ER
 
Q
nr
Sl
 +
 T
EM
-1
 +
 C
TX
-M
-5
5 
\ 
1 
EC
O
L 
Q
nr
Sl
+S
H
V
-1
 
1 
lK
LE
B
 
3(
18
.8
) 
SH
V
 
Q
nr
Sl
 +
 S
H
V
-2
 
1 
lK
PN
E 
Q
nr
Sl
+S
H
V
-1
1 
1 
1 
K
LE
B
 
1 
(6
.3
) 
TE
M
 +
 S
H
V
 
Q
nr
Sl
+T
EM
-l 
+ 
SH
V
-1
1 
1 
lK
PN
E 
1(
6.
3)
 
CT
X
-M
 
Q
nr
Sl
+C
TX
-M
-3
 
1 
lK
PN
E 
EA
ER
: E
nt
er
ob
ac
te
r a
er
og
en
es
.; 
EC
O
L:
 E
sc
he
ric
hi
a 
co
li;
 K
PN
E:
 K
le
bs
ie
lla
 pn
eu
m
on
ia
e;
 K
LE
B:
 K
le
bs
ie
lla
 s
pp
. 
5
7 
Chapter 3 Results 
3.8.2. Antimicrobial susceptibility of qnr isolates 
The antimicrobial resistance rates of gwr-positive and ^wr-negative isolates 
against antibiotics by disk diffusion test are shown in Table 3-8, the MICs and 
antimicrobial resistance rates of g^r-positive and ^^r-negative isolates against six 
quinolones by microbroth dilution method are shown in Table 3-9. 
In Table 3-8, all strains were susceptible to imipenem and were resistant to 
ampicillin. The resistance rates o fBLBL I including amoxicillin/clavulanate (90.5% 
vs 59.9%), cefoperazone/sulbactam (40.5% vs 22.8%) and piperacillin/tazobactam 
(42.9% vs 8.6%)’ and ceftazidime (52.4% vs 19.8%) in ^wr-positive isolates were 
significantly higher than that in gnr-negative isolates (P<0.05), whilst the resistance 
rates of gentamicin (26.2% vs 51.2%) in ^wr-positive isolates was significantly 
lower than that in gwr-negative isolates (P<0.05). 
When comparing g«r-positive and g^r-negative ofESBL-producing strains 例 二 
188), the resistance rates of BLBLI including amoxicillin^lavulanate (89.5% vs 
57.3%), cefoperazone/sulbactam (39.5% vs 23.3%) and piperacillinAazobactam 
( 3 9 . 5 0 / 0 vs 8.0%), and ceftazidime (50.0% vs 19.3%) in gwr-positive isolates were 
significantly higher than that in gwr-negative isolates (P<0.05). Whilst the resistance 
rates of gentamicin (26.3% vs 54.0%), cefotaxime (81.6% vs 94.7%) and 
sulfamethoxazole/trimethoprim (36.8% vs 58.7%) in g^r-positive isolates were 
significantly lower than that in ^wr-negative isolates (P<0.05). 
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When comparing ^wr-positive and ^wr-negative of PMAmpC-producing strains, 
the resistance rates of all antibiotics in ^wr-positive isolates were higher than that in 
^rwr-negative isolates except that of aminoglycosides. 
In Table 3-9, among 204 isolates, the quinolone resistance rates in ^wr-positive 
isolates were lower than that in gwr-negative isolates. The resistance rates of 
nalidixic acid (42.9% vs 82.1%), ciprofloxacin (54.8% vs 56.2%), fleroxacin (35.7% 
vs 56.8%), levofloxacin (35.7% vs 54.9%), moxifloxacin (35.7% vs 56.2%), 
norfloxacin (52.4% vs 56.2%) in ^wr-positive isolates were lower than that in qnr-
negative isolates. 
Among ESBL-producing strains, both quinolone resistance rates and MIC50 in 
^wr-positive isolates were lower than that in gwr-negative isolates. For those 
quinolone susceptible strains, the means of quinolone MIC values of gwr-positive 
isolates were higher than that in gwr-negative isolates. 
Among PMAmpC-producing stains, the quinolone resistance rates and MIC50 in 
^wr-positive were higher than that in gwr-negative isolates. For those quinolone 
susceptible strains, the means of quinolone MIC values of gwr-positive isolates were 
higher than that in gwr-negative isolates. 
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Table 3-8: Comparisons of antimicrobial resistance rates of ^rwr-positive & 
^rwr-negative isolates as determined by the disk diffusion method 
n . ‘• awr-positive strains ^r-negative strains 
A n t l b l 0 t l c No of R (% R) No. of R (% R) P v a l u e 
All isolates (N=204) (N=42) (N=162) 
Ampicillin 42 (100) 42(100) NA 
Imipenem 0 (0) 0 (0) NA 
Amikacin 1(2.4) 17(10.5) 0.130* 
Gentamicin 11 (26.2) 83 (51.2) 0.004 
Ceftazidime 22 (52.4) 32(19.8) <0.001 
Cefepime 13 (31.0) 38(23.5) 0.317 
Cefotaxime 34(81.0) 145 (89.5) 0.214 
Cefuroxime 38 (90.5) 155 (95.7) 0.243* 
Amoxicillin/clavulanate 38 (90.5) 97 (59.9) <0.001 
Cefoperazone/sulbactam 17 (40.5) 37 (22.8) 0.021 
Piperacillin/tazobactam 18(42.9) 14(8.6) <0.001 
Sulfamethoxazole/trimethoprim 26 (61.9) 98(60.5) 0.867 
ESBL-producing isolates (N=188) (N=38) (N=150) 
Ampicillin 38(100) 150(100) NA 
Imipenem 0 (0) 0 (0) NA 
Amikacin 1(2.6) 17(11.3) 0.130* 
Gentamicin 10(26.3) 81 (54.0) 0.002 
Ceftazidime 19(50.0) 29(19.3) <0.001 
Cefepime 13 (34.2) 38(25.3) 0.272 
Cefotaxime 31 (81.6) 142(94.7) 0.015 
Cefuroxime 35 (92.1) 147(98.0) 0.098 
Amoxicillin/clavulanate 34 (89.5) 86 (57.3) <0.001 
Cefoperazone/sulbactam 15 (39.5) 35 (23.3) 0.044 
PiperacillinAazobactam 15 (39.5) 12 (8.0) <0.001 
Sulfamethoxazole/trimethoprim 14 (36.8) 88 (58.7) 0.016 
PMAmpC-producing isolates CM=25) (N=26) 
(N=51) 
Ampicillin 25 (100) 26(100) NA 
Imipenem 0 (0) 0 (0) NA 
Amikacin 0(0) 3 (11.5) 0.235* 
Gentamicin 5 (20.0) 8 (30.8) 0.378* 
Ceftazidime 19(76.0) 6(23.1) <0.001* 
Cefepime 4(16.0) 0(0) 0.051* 
Cefotaxime 20(80.0) 11 (42.3) 0.014 
Cefuroxime 24 (96.0) 20 (76.9) 0.099 
Amoxicillin/clavulanate 25(100) 24 (92.3) 0.490 
Cefoperazone/sulbactam 7(28.0) 4(15.4) 0.451 * 
Piperacillin/tazobactam 15 (60.0) 4 (15.4) 0.003* 
Sulfamethoxazole/trimethoprim 18 (72.0) 9 (34.6) 0.007* 
p values with * were obtained by Fisher's Exact test, other P values without * were obtained by 
Pearson Chi-square test, NA = not applicable. 
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3.9. The Associations of qnr Genes with Other Bacterial 
Resistance Genotypes, and the Clinical Characteristics 
and Outcomes of Patients 
3.9.1 • Univariate analysis of the associations of qnr 
genes with other bacterial resistance genotypes, 
and the clinical characteristics and outcomes of 
patients 
The associations of qnr genes with other bacterial resistance genotypes, and the 
clinical characteristics and outcomes of patients are shown in Table 3-10. Co-
existence with the PMAmpC genes, hospital-acquired infection and history of solid 
tumour were more commonly identified in the ^wr-positive patients, Whereas co-
existence with CTX-M genes was more commonly identified in the gwr-negative 
patients. 
61 (29.9%) patients died during hospitalization and the overall 30-day mortality 
rate was 27.5% (56/204). In table 3-10，the 30-day mortality rate (47.6%) was 
significantly higher in the g^r-positive group (P<0.05). The associations of 30-day 
mortality with qnr genes, bacterial resistance genotypes and clinical characteristics 
of patients were shown in Table 3-11. Apart from ^wr-positive isolates infection, 
PMAmpC-positive isolates infection, polymicrobial bacteraemia infection, hospital-
acquired infection, development of pneumonia, previous exposure to penicillins and 
fluoroquinolones treatment, higher Pitt bacteraemia score and failure to receive 
appropriate susceptible antibiotics (carbapenems and fluoroquinolones) were 
associated with the 30-day mortality. There were 23 (11.3%) patients died in the 
first 48 hours of bacteraemia. Among 56 patients that died within 30 days after the 
onset of bacteraemia, 23 (41.1%) patients were given susceptible definitive 
antibiotics, 33 (58.9%) patients were not given any definitive antibiotics as they died 
soon after the laboratory report on susceptibility became available. 
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Table 3-10: Associations ofqnr genes with other bacterial resistance genotypes, 
and the clinical characteristics and outcomes of patients with bacteraemia 
qnr +ve qnr -ve 
Characteristic No. of patients No. of patients P value 
(%) N = 42 (%) N = 162 
Demographics 
Age 66.2士 17.2 70,1 士17.0 0.191 
Sex(Male) 18 (42.9) 73(45.1) 0.798 
Hostel resident 7(16.7) 42(24.9) 0.211 
Underlying disease 
Any one of the following co-morbidities 32(76.2) 110(67.9) 0.298 
Solidtomour 18 (42.9) 44 (27.2) 0.049 
Hematological malignancy 2(4.8) 10(6.2) 1.000* 
Liver cirrhosis 3 (7.1) 12 (7.4) 1.000* 
End stage of renal failure (ESRF) 0(0) 12(7.4) 0.132* 
Diabetes 13(31.0) 44(27.2) 0.626 
Heat failure 3 (7.1) 11 (6.8) 1.000* 
Immunosupressive treatment 3 (7.1) 23(14.2) 0.336 
History of medical treatment 
Hospital stay prior one year 36 (85.7) 138 (85.2) 1.000 
bivasive procedure prior one month 18(42.9) 35(34.6) 0.319 
IV catheter or other catheter prior one month 26 (61.9) 78 (48.1) 0.112 
Previous positive ESBL 13 (31.0) 42 (25.9) 0.513 
Antibiotics prior one month 23 (54.8) 90 (55.6) 0.927 
Antibiotics usage prior one month by drug group 
Penicillins 18 (42.9) 70(43.2) 0.206 
Cephalosporins 12 (28.6) 29 (17.9) 0.186 
Carbapenems 1 (2.4) 10(6.2) 0.466 * 
Fluoroquinolones 6 (14.3) 23 (14.2) 1.000 
Aminoglycosides 2 (4.8) 7 (4.3) 1.000 * 
Macrolides 0(0) 5(3.1) 0.586 * 
Others antibiotics 7 (16.7) 23 (14.2) 0.874 
Hospital-acquired infection 25(59.5) 58 (35.8) 0.005 
Source of bacteraemia 
Urinary tract infection 17(40.5) 78(48.1) 0.374 
Hepatobiliarytract&intra-abdominalinfection 13 (31.0) 44 (27.2) 0.626 
Pneumonia 6(14.3) 23 (14.2) 1.000 
Others infection 6 (14.3) 17 (10.5) 0.583* 
Presenting condition at the onset of bacteraemia 
Pitt bacteraemia score 2.7士2.6 2.5±2.2 0.562 
Severity ofillness (Pitt bacteraemia score > 4) 8(23.5) 9(19.1) 0.726 
ICU stay in this admission 9(21.4) 25(15.4) 0.486 
Bacterial isolates that isolated in bIood sample 
ESBL-positive 38 (90.5) 150 (92.6) 0.747 * 
PMAmpC-positive 25 (59.5) 26(16.0) <0.001 
CTX-M-positive 20 (47.6) 129 (79.6) <0.001 
TEM-positive 22 (52.4) 98 (60.5) 0.341 
SHV-positive 30(71.4) 5(3.1) <0.001 
Clinical outcomes 
30-daymortality 20 (47.6) 36 (22.2) 0.001 
P values with * were obtained by Fisher's Exact test, other categorical variables with P values without * 
were obtained by Pearson Chi-square test, P values for continuous variables were obtained by Student's 
t test. 
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= 二 二 、 = … ， 0 1 1 ” 0 0 - ^ m 0 r t a l h y i n p a t i e n t s w i t h bacteraemia with 
^ ^ b a c t e r i a l res»stance genotypes and clinical characteristics ofpatients 
Characteristic d^ed within 30 days after aIive within 30 days after 
the onset ofbacteraemia the onset ofbacteraemia p value 
N o . o f Patients (%) N = 56 No. of patients (%) N = 148 
Demographics 
Sex (Male) 力 广 … 、 
Age n ? ^ A ) 68 (45.9) 0.532 
^ 71.0± 16.2 68.6士 17.4 0.347 
Underlying disease 
Co-morbidities AA (n^ … 
Solidtumour 4 1 Io'? 101 (68 .2) 0 .491 
― 一 infection 31 5 ¾ ^ g ^ = 
source ofbacteraemia DZ ^ X L ) 0 0 0 9 
Urinyy tractinfection 16 (28.6) 79 (53 4) 0002 
Hepatobiliary tract mfection + intra-abdominal K ) a 0 0 2 
infection 15(26.8) 42 (28.4) 0.821 
Pneumonia 1 e n 0 n “ ， 
Otherinfection ^ ^ /人。4�)� <0.001 7 (12.5) 16 (10.8) 0.926 
History of medical treatment 
IV catheter or other catheter 川 m A nA /cn … 
Antibioticsprioronemonth ( 6) 7 4 ( 5 0 . 0 ) 0 .649 
S i = 。 — 31 (55.3) 57 (38.5) 0.030 
cLbatnemT 14 25'°) 27(18.2) 0.283 
Fluoroquinolones 1 3 ' 迅 H � . • * 
Aminoglycosides '3 f 4 f ^ �0 ;�8) 0 遍 
3(5.4) 6 (4.1) 0.708* 
Presenting condition at the onset ofbacteraemia 
Pi t tbac te raemiascore^=185) 36.2i3.9 2 2 1士 1 4 o o ^ 
Sev=y ofillness _ 8 5 ) 13 (32,5) 24 16 6) 0 045 
ICUadmiSS10n 11 (19.6) 23 (15.5) 0.623 
Medical treatment in this bacteraemia (received 
susceptible definitive antibiotics treatment) 
^ 7 ? n e 0 工， f o l l o w i n g t r e a t m e n t 23 (41.1) 128 (86.5) < 0 001 p-lactams/p-lactamase inhibitors 3 (5 4) 1 2 ) 8 n ' ^ 
Cephalosporins 2(3.6) 9(6.1) 0291* 
= : : e s 二 0 ) = . ) <0-001 
r 1
 & . , u ( u ) 17 (11.5) 0.004* 
Fluoroquinolones 4 (7.1) 38 (25.7) 0 003 
Bacterial isolates that isolated in blood sample 
Polymicrobial bacteraemia 13 (23.2) 14 ( 9 5 ) 0 0 1 0 
r = O S i t h ? 20(35-7) 22(14.9) 0.001 
ESBL-pos1t1ve 52 (92.9) 136 (91.9) 1.000 
r ^ M P P r 1 9 ( 3 3 .9 ) 32(21.6) 0.070 
CTX-M-pos1t1ve 37(66.1) 112(75.7) 0.168 
TEM-posmve 35 (62.5) 85 (57.4) 0 512 
SHV-P°Sltlve 18(32.1) 17(11.5) 0.001 
P values with * were obtained by Fisher's Exact test, other categorical variables with P values without * were 
obtained by Pearson Chi-square test, P values for continuous variables were obtained by Student's t test. 
6 4 
Chapter 3 Results 
3.9.2. Multivariate analysis of the associations of qnr 
genes with other bacterial resistance genotypes, 
and the clinical characteristics and outcomes of 
patients 
3.9.2.1. Multivariate analysis of the associations of qnr 
genes with other bacterial resistance genotypes, 
and the clinical characteristics of patients 
Factors that were found to have significance levels of P<0.1 in the univariate 
analysis, including co-existence with the PMAmpC genes, co-existence with CTX-
M genes, hospital-acquired infection and history of solid tumour were put into a 
backward, stepwise multivariate logistic model. By logistic regression analysis, 
presence of qnr gene was found to be independently associated with the presence 
with PMAmpC genes (P<0.001) and hospital-acquired infection (P<0.05), but not 
with other clinical characteristics of patients (Table 3-12), 
Table 3-12: Logistic regression ofvariables associated with qnrgenes. 
Characteristic P value Odds Ratio 95% CI 
PMAmpC-positive isolates <0.001 7.007 3.289-14.928 
Hospital-acquired infection 0.048 2.143 1.008 - 4.555 
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3-9"2-2- Multivariate analysis of the associations of 
mortahty with qnr genes, bacterial resistance 
genotypes and other clinical characteristics of 
patients 
Al l factors that were found to have significance levels of P<0.1 in univariate 
analysis for mortality, including ^r-positive isolates infection, PMAmpC-positive 
isolates infection SHV-positive isolates infection, polymicrobial bacteraemia 
infection, hospital-acquired infection, development of pneumonia, previous 
exposure to penicillins and fluoroquinolones treatment, higher Pitt bacteraemia score 
and failure to receive susceptible antibiotics (carbapenems and fluoroquinolones) 
were put into a multivariate Cox regression model to determine independent factors 
associated with higher mortality. The final model showed that development of 
pneumonia, failure to receive susceptible antibiotics (carbapenems and 
fluoroquinolones), and higher Pitt bacteraemia score were independently associated 
with mortality after it was adjusted by age and co-morbidities, whereas ^r-positive 
isolates infection was not shown to be an independent factor. 
Table 3-13: Cox regression of possible risk factors for mortality 
P v a l u e Z t 9 蘭 
received susceptible carbapenems treatment <0.001 0.222 0.103 — 0 480 
received susceptible fluoroquinolones treatment 0.003 0.193 0.065 — 0.572 
Pneumonia as the source of bacteraemia 0.001 3 . 7 9 5 \ . 7 3 4 一 g 296 
Pitt bacteraemia score 0.015 1.164 1.030— 1.316 
previous exposure to penicillins 0.014 2.294 1.186 — 4.439 
6 6 
Chapter 4 Discussion 
Discussion 
4.1. Prevalences and Susceptibility of ESBL and PMAmpC 
in Bacteraemic Enterobacteriaceae Isolates 
In this study, the prevalence of ESBL in bacteraemic Enterobacteriaceae 
was 19.8% (188/950). The prevalence of ESBL in Escherichia coli was 24.7% 
(142/575). It was higher than that in Europe (7.6%), North America (2.2%) and 
Asia-Pacific countries (0.5%- 24.5%) but similar to that in China (24.5%) [Hirakata 
et al., 2005; Reinert et al., 2007]. Besides, the prevalence ofESBL in Klebsiella spp. 
was 10.2 % (24/236) and was lower than that in Latin America (44.0%), other Asia-
Pacific countries (22.4%) and was comparable to Europe (13.3%) and higher than in 
North America (7.5%) [Reinert et al, 2007]. The prevalences of ESBL in different 
species appeared to vary in different geographical regions. 
Among these 188 ESBL-producing isolates, 120 (63.8%)，35 (18.6%) and 
149 (79.3%) harbored blaTEu , blasm and blacix-u genes respectively. The blacix-u 
gene (79.3%) was the most prevalent ESBL gene in our isolates. A total of 4 (2.5%) 
isolates harbored bla genes for non-TEM, non-SHV and non-CTX-M. In 1980s, the 
ESBLs were predominately TEM and SHV derivatives [Bradford, 2001]. However, 
since 2000, the CTX-M p-lactamases, originally described in South America, Asia 
and Europe, have spread worldwide [Bonnet, 2004]. This might be an explanation 
for the high prevalence of blacix-u gene in our isolates. 
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These ESBL-producing isolates were multi-drug resistant. The data in our 
study showed that co-resistance occurred not only to cephalosporins but also to other 
classes of antibiotics such as aminoglycosides and fluoroquinolones. 60.6% of 
ESBL-positive isolates were resistant to one or more fluoroquinolones. This 
indicated serious therapeutic problems would be faced by the clinicians that i f such 
infection occurs, carbapenems would be the only appropriate therapeutic choice. 
The prevalence of PMAmpC in bacteraemic Enterobacteriaceae was 5.4% 
(51/950). The prevalence of PMAmpC in Escherichia coli and Klebsiella spp were 
2.6% (15/575) and 8.5% (20/236) respectively and were comparable to similar 
findings from China [Ding et al, 2008]. This can be explained by short geographic 
distance between China and Hong Kong. 
Among these 51 PMAmpC-producing isolates, 28 (54.9%) isolates harbored 
the DHA-type bla\mvcgenes, 12 (23.5%) isolates harbored EBC-type b la^cgenes 
and 11 (21.6%) isolates harbored CIT-type Z?/aAmpCgene. DHA-type was the most 
prevalent bla\mvc gene in our isolates and was comparable to report from China 
[Ding et al, 2008]. This can be also explained by short geographic distance between 
China and Hong Kong. 
These PMAmpC-producing isolates were multi-drug resistant. They showed 
high rates of resistance to amoxicillin/clavulanate. More than 50% of isolates were 
resistant to ceftazidime, cefotaxime and cefuroxime and about 50% were also 
resistant to fluoroquinolones. Most of the isolates remained susceptible to cefepime 
and carbapenems. Again, clinicians would face the same serious therapeutic 
problems i f such infections are encountered, carbapenems would be the only 
appropriate therapeutic choice. 
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4.2. Epidemiology of Plasmid-mediated Quinolone 
Resistance (qnr) Genes 
qnr genes {qnrA, qnrB and qnrS) have been identified worldwide [Martinez-
Martinez et al” 1998; Jacoby et al” 2006; Jacoby et al” 2003; Rodriguez-Martinez 
et al, 2003; Gay et al., 2006; Poirel et al, 2006; Pai et al., 2007; Xu et al, 2007; 
Cheung et al., 2005; Chu et al., 2006; Cattoir et al, 2007b; Park et al, 2007; Wu et 
al., 2007; Wang et al., 2008]. Their overall prevalence ranged from 0.2% to 87%, 
depending on the criteria used in strain selection (e.g. resistance to ceftazidime, to 
nalidixic acid, to fluoroquinolones or produce ESBL or produce AmpC). To our 
knowledge, this is the first report of qnrB and qnrS genes identified in Hong Kong. 
In our study, 42 (20.6%) isolates harbored qnr genes. Twenty-six (12.8%) isolates 
harbored qnrB gene and 16 (7.8%) isolates harbored qnrS gene. None of these 
isolates harbored qnrA gene and no single isolate carried more than one type of qnr 
genes. Among these ^wr-positive isolates, 34 (80.9%) isolates were Klebsiella spp., 
4 (9.5%) isolates were Escherichia coli, 2 (4.8%) were Citrobacter spp. and 2 (4.8%) 
were Enterobacter spp. 
In comparison to the findings from other countries with similar selection 
criteria (ESBL- or PMAmpC- producers or blood samples), more qnr genes were 
found in Hong Kong than that in Canada (2.9%), Israel (3.4%), Sweden (4.0%)， 
Bulgaria (4.2%), Hungary (4.2%), Taiwan (4.4%), Kuwait (4.7%), Spain (4.9%), 
Turkey (6.4%), USA (6.7% ) and Alabama (18.0%) [Castanheira et al., 2008; 
Cattoir et al, 2007b; Fang et al” 2009; Jacoby et al, 2003; Lavilla et al, 2008; 
Oktem et al, 2008; Poirel et al, 2006; Sabtcheva et al, 2009; Strahilevitz et al, 
2007; Szabo et al” 2008; Wu et al, 2008]. On the other hand, fewer qnr genes were 
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found in Hong Kong than that in United Kingdom (31.9%) and South Korea (38.3%) 
[Corkill et al., 2005; Tamang et al., 2008]. Our finding was similar to those reported 
in China (23.4%) and Thailand (24.4%) [Poirel et al., 2005c; Wang et cd” 2008]. 
Our study had shown that qnrB was predominant among the three qnr determinants 
detected. Similar findings were also reported in USA [Castanheira et al., 2008], 
Bulgaria [Sabtcheva et al., 2009], Sweden [Fang et al., 2009], Kuwait [Cattoir et al, 
2007b], Taiwan [Wu et aL, 2008], South Korea [Kim et al, 2009, Tamang et al, 
2008] and Israel [Strahilevitz et al., 2007]. On the other hand, qnrA was 
predominant in Hungary [Szabo et aL, 2008], Spain [Lavilla et al,, 2008], Turkey 
[Oktem et al, 2008] and France [Lavigne et aL, 2006]. No qnrA gene was detected 
in our study, in accordance to a similar finding that was found in Bulgaria 
[Sabtcheva et al, 2009], Sweden [Fang et al, 2009], Kuwait [Cattoir et aL, 2007b] 
and Taiwan [Wu et aL, 2008]. Therefore, the prevalent type of qnr genes appeared 
to vary between different geographical areas and further study on their evolution and 
transmission is needed.^r gene was found more frequently in Klebsiella 
pneumoniae than in other Enterobacteriaceae in our study (Table 3-6 & Table 3-7). 
Similar fmdings were also found in Alabama [Jacoby et al., 2003], USA [Rodriguez-
Martinez et al, 2003; Wang et aL, 2004a], Spain [Lavilla et al, 2008], China [Jiang 
et aL, 2008], Taiwan [Wu et aL, 2008], South Korea [Pai et al., 2007], Turkey 
[Oktem et al., 2008], and Hungary [Szabo et aL, 2008]. However, other studies 
reviewed that qnr gene was found more frequently in Enterobacter cloaceae in UK 
[Corkill et aL, 2005] and France [Cambau. et al, 2006]. It suggested that qnr gene 
was more prevalent among Klebsiella pneumoniae than other Enterobacteriaceae 
such as Escherichia coli. This might be explained by the fact that the qnrA and qnrB 
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genes were firstly discovered in Klebsiella pneumoniae isolates. The bacterial cells 
tend to take up extra-chromosomal DNA to gain survival advantage in the presence 
of selective pressure. Therefore, a long time span and a continuous antibiotics 
(fluoroquinolones) selective pressure are required for qnr genes to disseminate from 
Klebsiella spp. to other species. Besides，qnr plasmids might have different 
stabilities in Enterobacteriaceae. Researchers reported that when Escherichia coli 
(E. coli J53 or E. coli HB101) were used in conjugation experiments, qnr plasmids 
were found non-conjugative and some qnr genes were lost during the process [Wang 
et al, 2003; Wang et aL’ 2004a; Rodriguez-Martinez et al, 2003]. This phenomenon 
suggested that qnr plasmid may be unstable in some species such as Escherichia coli. 
More investigation is needed to study the stability of qnr plasmid among 
Enterobacteriaceae. 
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4.3. Genotypes of qnr-positive Isolates 
Among the ESBL-/PMAmpC-producers, the ^wr-positive isolates most 
frequently co-existed with PMAmpC (DHA-1), SHV-11, CTX-M-14 and TEM-1 
genes. Some researchers suggested that qnrB and qnrS genes were carried by two 
different size and different genetic mobile elements in plasmids [Bonemann e/ aL, 
2006; Garcfa-Fernandez et al, 2009; Kehrenberg et aL, 2006; Kehrenberg et al., 
2007; Verdet et al, 2006; Wu et al., 2008]. In our result, ^rB-posit ive isolates 
frequently co-existed with DHA-1 and SHV-11 genes, while —S-positive isolates 
frequently co-existed with TEM-1, SHV and CTX-M genes and none of them co-
existed with PMAmpC (DHA-1) genes. More importantly, these antibiotics 
resistance genes and qnr genes may be carried on the same plasmid which allows 
them to disseminate horizontally and rapidly [Hu et al., 2008; Pai et aL, 2007; Poirel 
etal.，2007]. 
In our study, 23 (88.5%) out of 26 —B-positive isolates were qnrBA, 1 
(3.8%) isolate was qnrB^ and 2 (7.7%) isolates were either qnrB6 or qnrB9. qnrB-
positive isolates were associated with PMAmpC (DHA-1) gene and SHV genes. 
Most of them (23/26, 88.5%) co-existed with DHA-1 genes, 73.1% (19/26) co-
existed with SHV genes, 38.5% (10/26) co-existed with TEM-1 genes, 30.8% (8/26) 
co-existed with CTX-M genes and 7.7% (2/26) co-existed with bla genes for CMY. 
Previous studies showed a strong association between qnrBA and DHA-1 gene in 
China [Yang et al, 2008]，France [Verdet et aL, 2006], South Korea [Tamang et al., 
2008; Pai et al, 2007], Switzerland [Liassine et al, 2008] and Taiwan [Wu et al, 
2008] in accordance to our findings. Other studies showed that qnrB4 was 
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associated with CTX-M-14 [Jiang et al, 2008; Pai et al, 2007] and CTX-M-15 
[Liassine et aL, 2008] and SHY-12 [Tamang et al., 2008; Cattoir et al, 2007a; Pai et 
al, 2007] which were similar to our findings. In our study, there were 6 qnrBA 
isolates co-existed with CTX-M-14, 1 qnrB4 isolate co-existed with CTX-M-15 and 
2 qnrB4 isolates co-existed with SHV-12. On the other hand, no previous reports 
showed that qrtrB4 was associated with SHV-11, SHV-31 and TEM-1, but in our 
study, 9, 9 and 2 qnrB4 isolates co-existed with SHV-11, TEM-1 and SHV-31 
respectively. In addition, some previous studies showed that qrtrB4 was associated 
with TEM-52 [Pai et al, 2007], CTX-M-3 [Jiang et al, 2008; Liassine et al, 2008], 
CTX-M-9 [Liassine et al, 2008] but in our study, none of these ESBL genes co-
existed with qnrBA isolates. In general, we observed that gwrB-positive isolates 
frequently co-existed with other PMAmpC and ESBL genes. It suggested that qnr 
genes with certain PMAmpC and ESBL genes are frequently co-transmitted. It 
might be explained by the genetic linkage between these resistant genes on plasmid. 
Previous studies reported that qnr genes with certain PMAmpC and ESBL genes 
were frequently found on the same plasmid. For instance, qnrB4 frequently co-
existed with PMAmpC gene (DHA-1) because both of them were found in the same 
genetic mobile environment, they were found in plasmid that contains sull-typQ 
integron that included orf513 recombinase [Verdet et aL, 2006]. 
In our study, all 16 qnrS-positiwQ isolates were qnrSl. Controversy exists in 
the literature surrounding the co-existence of other resistance genes on qnrS plasmid. 
Some reports showed that the sizes of qnrS plasmids were smaller than qnrA and 
qnrB plasmids and thus they seldom carry other ESBL or PMAmpC genes 
[Bonemann Qt al, 2006; Garcia-Fernandez et al, 2009; Kehrenberg et al., 2007; Wu 
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et al, 2008]. This might explain why none of our ^rS-positive isolates co-existed 
with Z>/flAmpc genes. On the other hand, results in our study agreed with the reports 
that some bla genes that co-existed with ^rSl-posit ive isolates. Coexistence of 
^ S 1 gene with TEM-1, SHV and CTX-M genes were reported. A total of 12 
^rSl-posi t ive isolates co-existed with TEM-1 in our study, which agreed with the 
findings in previous reports [Hata et al, 2005; Gay et al, 2006; Hu et al., 2008]. 
One isolate co-existed with SHV-2, such co-existence was also reported previously 
in Taiwan and China [Chen et al, 2006; Yang et al, 2008]. Three isolates co-existed 
with CTX-M-14, such co-existence was reported in China [Yang et al” 2008]. 
^rSl-harboring isolates co-existed with other SHV and CTX-M genes were also 
observed. These data suggested that gwrSl-harboring isolates, which co-existed with 
other ESBL genes, are particularly found in Asia. 
To better elucidate the association of qnr genes with other bla genes, more 
investigations are needed. For example, study on the transferability and mobility of 
genetic elements in the ^nr-harboring plamids. Conjugation experiments can be used 
to study the transferability of genetic elements and plasmid profiles can be obtained 
by primer walking technique to study the genetic linkage between these resistance 
genes on plasmid. Without the data for the profiles of the ^wr-positive plasmids, we 
may not confirm that the qnr genes and the co-existed bla genes were on the same 
plasmid but it was rare for a cell contains more than 1 plasmid. 
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4.4. Antimicrobial Susceptibility of gnr-positive Isolates 
In this study, gwr-positive isolates were found more resistant than qnr-
negative isolates towards multiple antibiotics, especially BLBLI and ceftazidime. It 
might be explained by the co-existence of qnr genes and ESBL and/or PMAmpC 
genes on the same plasmid as discussed in section 4.3. The qnr genes, together with 
ESBL and/or PMAmpC genes were co-transmitted and hence co-resistance was 
observed in ^wr-positive isolates. In fact, cephalosporins and BLBLI are first-line 
drugs for nosocomial infections and are frequently used in our hospital. As qnr-
positive isolates had a higher chance of resistance to these antibiotics, treatment with 
these antibiotics in patients infected with ^wr-positive isolates apparently may link to 
a worse outcome such as bacteraemic infection. 
Among ESBL-producing isolates, the resistance rates of nalidixic acid 
(44.7% vs 87.3%), ciprofloxacin (57.9% vs 60.0%)，fleroxacin (36.8% vs 60.7%), 
levofloxacin (36.8% vs 58.7%), moxifloxacin (36.8% vs 60.0%) and norfloxacin 
(55.3% vs 60.0%) in ^wr-positive isolates were lower than that in gwr-negative 
isolates. Besides, the means of fluoroquinolone MIC values of fluoroquinolone 
susceptible ^r-posit ive isolates were higher than that in gwr-negative isolates. 
These findings were similar to those reported in other studies. Researchers 
demonstrated that an acquired qnr gene to a wild-type Escherichia coli strain (E. 
coli J53 or E. coli HB101) would render a wild-type Escherichia coli strain 
remained susceptible to fluoroquinolone according to CLSI clinical breakpoints 
[Hata et al, 2005; Hu et aL, 2008; Jacoby et al, 2006; Wang et al, 2004b]. Most of 
the studies investigated the effect of qnr genes on fluoroquinolone MICs by 
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measuring the differences in fluoroquinolone MICs for a wild-type Escherichia coli 
strain (E. coli J53 or E. coli HB101) with and without ^wr-positive plasmid. Some 
reports showed that ciprofloxacin MICs increased from 0.008 mgfL to 0.25 mg/L in 
the presence of qnrA-, qnrB- and ^wrS-positive plasmid in wild-type Escherichia 
coli strain [Hata et al, 2005; Hu et al, 2008; Jacoby et al, 2006; Wang et al, 
2004b]. Besides, levofloxacin MICs increased from 0.015 m g l to 0.5 mg/GL, 0.5 
m g ^ and 0.38 mg/L in the presence of qnrA-, qnrB^ and ^nrS-positive plasmid 
respectively in wild-type Escherichia coli strain piata et aL，2005; Hu et al, 2008; 
Jacoby et al., 2006; Wang et aL, 2004b]. In addition, moxifloxacin MICs increased 
from 0.03 m g ^ to 0.5 mgfL and 1 mg^, in the presence ofqnrA- and ^wrB-positive 
plasmid respectively in wild-type Escherichia coli strain [Jacoby et aL, 2006; Wang 
et aL, 2004b]. Furthermore, nalidixic acid MICs increased from 4 mg/L to 16 mgfL 
in the presence of qnrA-, qnrB- and ^rS-positive plasmid in wild-type Escherichia 
coli strain [Hata et aL, 2005; Hu et al., 2008; Jacoby et al., 2006; Wang et al., 
2004b]. In general, the presence of gwr-positive plasmid increased fluoroquinolone 
MICs by 16 to 33 times. However, a lesser increase (4 times) was found in MIC of 
nalidixic acid [Hata et al., 2005; Hu et al, 2008; Jacoby et al, 2006; Wang et al, 
2004b]. 
On the contrary, among PMAmpC-producing isolates, the resistance rates of 
nalidixic acid (56.0% vs 46.2%), ciprofloxacin (68.0% vs 30.8%), fleroxacin (48.0% 
vs 30.8%), levofloxacin (48.0% vs 30.8%), moxifloxacin (48.0% vs 30.8%) and 
norfloxacin (68.0% vs 30.8%) in ^wr-positive isolates were higher than that in qnr-
negative isolates. Higher fluoroquinolone resistance rates observed in ^wr-positive 
isolates might be due to other resistance mechanisms (such as gyrA, parC mutations 
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or efflux pumps, etc.) rather than conferred by qnr genes. For instance, the firstly 
discovered quinolone resistant isolate with qnrAl also exhibited chromosomal 
mutations (DNA gyrase, topoisomerase IV, efflux or outer membrane porin channels) 
for fluoroquinolone resistance [Jeong et al., 2008; Martinez-Martinez et al, 2008]. 
Besides, Martinez-Martinez, Poirel and colleagues hypothesized that the presence of 
qnr gene would provide a favourable background for the selection of additional 
chromosomally-encoded fluoroquinolone resistance mechanisms which lead to 
subsequently high-level fluoroquinolone resistant [Martinez-Martinez et al” 1998; 
Martinez-Martinez et al, 2003; Poirel et al” 2006]. Martinez-Martinez and 
colleagues showed that the frequency of spontaneous mutations to ciprofloxacin or 
nalidixic acid resistance was more than 100 times in the presence of qnr genes 
[Martinez-Martinez et al.，1998]. Also, in-vitro studies showed that when qnrA gene 
was expressed in a porin-deficient strain, the MICs of ciprofloxacin, levofloxacin 
and moxifloxacin increased from 8 to 32 times, reaching the MIC values to 4-8 
v^gfL [Martinez-Martinez et al, 2003]. In addition, Poirel and colleagues showed 
that when the qnrA gene was expressed in an Escherichia coli which did not have 
any classic fluoroquinolone resistance mutations, they subsequently developed high-
level resistance after 5 days of norfloxacin therapy [Poirel et al., 2006]. Furthermore, 
higher fluoroquinolone resistance rates observed in our gwr-positive PMAmpC-
producing isolates might also support the hypothesis. 
To better elucidate the fluoroquinolone resistance mechanisms in both qnr-
positive and ^wr-negative fluoroquinolone-resistant Enterobacteriaceae isolates, 
more investigations may be required. For example, detect the presence of mutations 
in gyrA and parC genes within the quinolone resistance-determining region (QRDR) 
7 7 
Chapter 4 Discussion 
by PCR assays. Otherwise, we could not neglect the effect of mutations in gyrA and 
ParC genes in QRDR on fluoroquinolone MICs of fluoroquinolone-resistant 
Enterobacteriaceae isolates. The mutations in gyrA and parC genes in QRDR 
conferred ‘high-level，fluoroquinolone resistance and thus our interpretation on the 
effect of^wr genes ofal l fluoroquinolone-susceptible strains would be correct. 
Although qnr genes caused 'low-level' fluoroquinolone resistance, many 
studies showed that they facilitated the selection of higher quinolone resistance 
[Martinez-Martinez et aL, 1998; Martinez-Martinez et al, 2003; Poirel et aL, 2006]. 
Once ^r-posit ive stains with ‘low-level，fluoroquinolone resistance are induced to 
higher-level fluoroquinolone resistance, they may reduce the efficacy of 
fluoroquinolones therapy in patients infected with qnr-positl\Q strains. Therefore, 
continuous surveillance for qnr genes in clinical isolates is necessary. 
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4.5. The Associations of qnr Genes with Other Bacterial 
Resistance Genotypes, and the Clinical Characteristics 
of Patients 
To our knowledge, no previous study has investigated the associations of qnr 
genes with other bacterial genotypes, and the clinical characteristics of patients. Co-
existence with the PMAmpC genes, hospital-acquired infection and history of solid 
tumour were more commonly identified in the ^r-posit ive patients. No association 
was found between qnr genes and prior exposure to fluoroquinolones. It may be due 
to only six patients infected with ^wr-harboring isolates have prior exposure of 
fluoroquinolones and thus may have limited the ability to determine the association 
between them. 
Factors that were found to have significance levels ofP<0.1 in the univariate 
analysis were put into a backward, stepwise logistic regression model. However, the 
final model showed that presence of qnr genes was independently associated with 
the presence of PMAmpC genes and hospital-acquired infection, but not with other 
clinical characteristics of patients. Significant association was found between 
PMAmpC-positive strains with the qnr genes (P<0.001). It might be explained by 
the genetic linkage between these resistant genes on the same plasmid as discussed 
in section 4.3. No significant association was found between CTX-M-positive 
isolates and qnr genes. It might be explained by the fact that most of our isolates 
(73.0%) were CTX-M-positive and hence the difference of the presence of CTX-M 
between ^wr-positive and gwr-negative might be small and statistically insignificant. 
Besides, most (86.6%) of the CTX-M-positive isolates were Escherichia coli and 
only four out of 146 (2.7%) Escherichia coli isolates were harbored qnr genes and 
hence no significant association was found between CTX-M-positive isolates and 
qnr genes. 
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4-6. The Associations of Mortality with qnr Genes, Bacterial 
Resistance Genotypes and Other Clinical 
Characteristics of Patients 
Mortality rate was high in our study. The 30-day mortality rate was 27.5% 
(56/204). On univariate analysis,妒广-positive isolates infection, PMAmpC-positive 
isolates infection, SHV-positive isolates infection, polymicrobial bacteraemia 
infection, hospital-acquired infection, development ofpneumonia, prior exposure to 
penicillins and fluoroquinolones, higher Pitt bacteraemia score, failure to receive 
susceptible antibiotics (carbapenems, and fluoroquinolones) were associated with 
higher mortality. 
A l l the above factors were put into a multivariate Cox regression model for 
survival analysis. It showed that development of pneumonia, failure to receive 
susceptible antibiotics (carbapenems and fluoroquinolones) and higher Pitt 
bacteraemia score were significant risk factors for mortality (P<0.05). The presence 
ofqnr gene was not. 
The presence of qnr gene was not found to be an independent factor for 
mortality; it suggested that qnr gene itself was not associated with higher bacterial 
virulence, and it was confounded by other risk factors leading to higher mortality. 
Patients infected with ^wr-positive isolates might be more severely ill, such as higher 
Pitt bacteraemia score and development of pneumonia. Most importantly, higher 
mortality of patients infected with ^wr-positive isolates may be associated with 
increased risk of inappropriate/non-susceptible antibiotic treatment due to multi-
drug resistant characteristics of g«r-positive isolates, which, in turn, may lead to 
treatment failure and patient death. 
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In fact, all of our recruited patients were infected with ESBL- and/or 
PMAmpC-producing isolates, so carbapenems is the most effective antibiotics to 
treat them [Kang et al, 2004; Reinert et al, 2007] and fluoroquinolones ( i f 
susceptible) would be another therapeutic alternative [Kang et al, 2004]. Besides, 
Kang and colleagues also showed that bacteraemic patients infected with ESBL-
producing Escherichia coli and Klebsiella pneumoniae received definitive 
carbapenems (12.9%) or fluoroquinolones (ciprofloxacin) (10.3%) had lower 30-day 
mortality rates than patients who received cephalosporins or aminoglycosides 
(26.9%), although not statistically significant [Kang et al, 2004]. In addition, 
Paterson and colleagues also showed that the mortality rate for patients infected with 
ESBL-producing orgainsims received carbapenem in the first 5 days (5%) was 
significantly lower than patients that received a noncarbapenem (43%) (P=0.001) 
[Paterson et aL, 2004]. Therefore, a lower mortality rate in patients with susceptible 
carbapenems and fluoroquinolones was observed. 
Besides, Pitt bacteraemia score reflects the severity of illness, high Pitt 
bacteraemia score meant that the patient was severely i l l and associated with high 
mortality rate [Daikos et al, 2007; Lee et al, 2006]. In addition, Al-Hasan and 
colleagues also reported that the respiratory source of bloodstream infection was 
associated with a higher 28-day mortality which was similar to our findings [Al-
Hasan et al, 2010]. Therefore, development of pneumonia and higher Pitt 
bacteraemia score were significant risk factors for mortality. 
8 1 
Chapter 4 Discussion 
4.7. Clinical Importance and Clinical Implications of qnr 
Genes 
Our study showed that plasmid-mediated quinolone resistance caused by qnr 
genes is a clinically significant problem. A higher prevalence (20.6%) ofqnr genes 
was found in ESBL- and/or PMAmpC-producing Enterobacteriaceae, especially in 
Klebsiella pneumoniae. Besides, ^wr-positive isolates were multi-drug resistant 
strains and were found to be associated or linked with PMAmpC genes (DHA-1), 
SHV genes (SHV-12), CTX-M genes (CTX-M-14, CTX-M-15) and TEM-1 genes in 
plasmids. It is possible that the qnr genes, together with bla genes, can transfer 
horizontally and disseminate rapidly through plasmids. In addition, although qnr 
genes lead to ‘low-level，fluoroquinolone resistance only, they may provide a 
favourable background to the selection of additional chromosomally-encoded 
fluoroquinolone resistance mechanisms which subsequently render the organism 
becomes high-level fluoroquinolone resistant. Furthermore, their presence can limit 
the therapeutic choice, as the gwr-positive isolates were commonly found to be 
resistant to multiple antibiotics, including BLBLI. It is very worrisome that 
clinicians are not able to prescribe the appropriate antibiotics to patients infected 
with gwr-positive isolates, as it may result in higher mortality rate, as failure to 
receive susceptible antibiotics were associated with higher mortality in this study. 
Finally, recent previous reports showed the emergence of plasmid-mediated KPC-2 
carbapenemase and qnrB on the same plasmid in Klebsiella pneumoniae in China 
[Mendes et al, 2008] and in Enterobacter cloacae in Israel [Chmeinitsky et al, 
2008]. It is possible that these carbapenem resistant isolates with the presence of qnr 
gene may subsequently developed high-level fluoroquinolone resistance that further 
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limits the therapeutic choice. Therefore, it is important to monitor the prevalences of 
q n r gene and fluoroquinolnes resistance in Enterobacteriaceae especially in 
Klebsiella pneumonia, as qnr gene was found more frequently in Klebsiella 
pneumonia in this study. 
There are three possible strategies to prevent and control the emergence and 
spread of such resistant organisms. First, the antibiotic stewardship program should 
be set up to optimize the use of antibiotics and to educate clinicians on the prudent 
use of antimicrobial agents. Particularly, restriction on the use of fluoroquinolones 
can be used for combating fluoroquinolone resistance. As the selection pressures of 
exposure to fluoroquinolones can promote the occurrence of fluoroquinolone 
resistance by providing a survival advantage to bacteria that acquired the resistance 
gene. Indeed, some scientists have demonstrated the positive effects ofrestriction of 
fluoroquinolone use on the reduction of fluoroquinolone resistant isolates [Aubert et 
al , 2005; Saito et al, 2008]. In addition, high prevalence of qnr genes was found in 
ESBL- and/or PMAmpC-producing isolates. This may suggest that ESBL and 
PMAmpC isolates appeared to provide favourable background for the selection of 
qnr gene. Therefore, restriction on the use of third-generation cephalosporins may 
reduce the prevalence of ESBL- and/ or AmpC-producers, which, in turn, may 
reduce the prevalence of qnr genes. 
Further still the continuous monitoring of qnr-, ESBL-, PMAmpC- and 
carbapenemase-producers is of great importance. International antimicrobial 
resistant surveillance programs such as SENTRY, MYSTIC and TEST have 
provided important data. In addition, local hospital antimicrobial resistant 
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surveillance program with the cooperation of microbiologists, infection-control 
doctors and technicians in the microbiology laboratory may provide real-time, local 
important data. Continuous monitoring is necessary to provide information to 
clinicians for selecting the appropriate initial therapy, switching to other proper 
antimicrobial agents when needed and to evaluate the extent of the spread of the 
resistant organisms. 
Furthermore, as qnr genes were associated with hospital-acquired infection 
and thus infection control measures should be imposed on all health care workers to 
follow strictly. Antimicrobial resistant organisms are spread through direct and 
indirect contact. Therefore, contact precautions with wearing of gloves and 
protective gowns and most importantly washing hands after contact with patients 
and before leaving the wards are pertinent, as well as formal disinfection to 
eliminate the source for cross-transmission within the hospital. 
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4.8. Limitations of the Current Study 
There are several potential limitations in our study. First, our investigation is 
a local study but most of our results were comparable to findings in other regions 
and thus our results would probably be useful to other regions. 
Secondly, reliable data on prior antibiotic exposure were available up to one 
month before the onset of bacteraemia but not available beyond one month. In 
addition, reliable data on prior antibiotic exposure in an outpatient setting were also 
not available. As a result, data on prior antibiotic exposure were limited. In 
particular, available data on prior exposure to fluoroquinolones were small, it may 
limit the ability to identify prior exposure to fluoroquinolones as a risk factor for the 
acquisition of qnr genes. 
Thirdly, high mortality rate was observed in patients with ^2r-harb0ring 
isolates. In an attempt to find out the independent factors for mortality, many 
confounders were obtained. Multivariant model was then used to analyze the data so 
as to minimize all confounding factors. 
Fourthly, despite the fact that new qnr variants might have emerged and lists 
updated at www.lahey.org/qnrStudies and may not be covered by the current PCR 
methods as the primers may not fully match the variant DNA. Specific degenerate 
primers could be designed based on all 33 known sequences that were available 
from GenBank for the detection of the qnr genes, so as to minimize any chance for 
missing the detection of qnr genes. 
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Finally, we did not analyse the genetic mobile elements in ^r-positive 
plasmid and QRDR mutations of the gyrA and parC genes in ESBL-/PMAmpC 
bacteraemic Enterobacteriaceae and thus further investigations are needed to made 
a detailed interpretations for the association of qnr genes with other resistance genes 
and the impact of qnr genes on fluoroquinolone susceptibilities among ESBL-
^MAmpC-positive Enterobacteriaceae isolates. Without the profiles of the qnr-
positive plasmids, we may not confirm that the qnr genes and the co-existed bla 
genes were on the same plasmid but it was rare for a cell contains more than 1 
plasmid. Also, without the absence of mutations in gyrA and parC genes in QRDR, 
we could not neglect the effect of mutations in gyrA and parC genes in QRDR on 
fluoroquinolone MICs of fluoroquinolone-resistant Enterobacteriaceae isolates. The 
mutations in gyrA and parC genes in QRDR conferred ‘high-level, fluoroquinolone 
resistance and thus our interpretation on the effect of qnr genes of all 
fluoroquinolone-susceptible strains would be correct. 
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4.9. Future Studies 
This study has led to various opportunities for future work to be done. 
(1) Study the clinical impact of qnr genes. For example, study the effect of 
科 genes on the efficacy of fluoroquinolone and/or fluoroquinolone-
containing treatment. It may provide important information for 
clinicians to prescribe appropriate antibiotics to patients. 
(2) Study risk factors for the acquisition of qnr genes in other clinical 
settings or populations. It may provide guidance on the control of its 
dissemination. 
(3) Study the association of qnr genes with the increasing rates of 
fluoroquinolone resistance. It may provide guidance on the control ofits 
dissemination. 
(4) Study genetic association between qnr, ESBL and PMAmpC genes by 
investigating the genetic environment and array of qnr, ESBL and 
PMAmpC genes on plasmids. 
(5) Set up a rapid and reliable detection method for qnr genes. Nowadays, 
the detection method of qnr genes relied on PCR amplification followed 
by sequencing. This detection method is time-consuming and expensive, 
so it is very difficult to set up in the current clinical routine setting and 
thus a rapid and reliable detection method is needed for continuous 
monitoring of qnr genes. 
8 7 
Chapter 4 Discussion 
(6) Study of plasmid-mediated quinolone resistance mechanisms. The 
discovery of plasmid-mediated quinolone resistance mechanisms was 
within the last decade and new plasmid-mediated quinolone resistance 
mechanisms might be discovered. For example, the quinolone 
hydroxylation resistance mechanism demonstrated in some fungi has 
also found in bacteria. 
(7) Further investigations for my current study: (i) two Citrobacterfreundii 
isolates were found to harbor the CIT-type blaAmpC gene. However, the 
DNA sequences of these two isolates did not fully match with 
sequences that were available from GenBank and thus further 
investigations (plasmid transferability testing, plasmid profile) wil l be 
followed to characterize these new variants of CIT-type blaAmpC genes, 
(ii) Conjugation experiments and plasmid profile analysis could be done 
on all ^r-posit ive isolates in order to investigate the transferability and 
mobility ofthe genetic elements that associated with qnr genes. 
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4.10. Conclusions 
To our knowledge, this is the first report on the presence of qnrB and qnrS 
genes in clinical isolates in Hong Kong. Plasmid-mediated quinolone resistance 
caused by qnr genes is a clinically significant problem. High prevalence (20.6%) of 
qnr genes was found in ESBL- and/or PMAmpC-producing Enterobacteriaceae, 
especially in Klebsiella pneumoniae. These were multidrug-resistant strains that 
frequently co-existed with other resistant genes (ESBL and PMAmpC genes) and 
qnr genes together with bla genes were found to be able to disseminate rapidly 
through plasmids. In addition, qnr genes may provide a favourable background in 
which the selection of additional chromosomally-encoded fluoroquinolone 
resistance mechanisms can occur and to develop high-level fluoroquinolone 
resistance. The emergence of high-level fluoroquinolone resistance would further 
limit the therapeutic choice. Therefore, continuous monitoring of these resistant 
strains and their antimicrobial susceptibility profiles, particularly among the ESBL-
^MAmpC-producers is needed; and infection control measures should be strictly 
adhered to prevent dissemination of these resistant organisms. 
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